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Targeting	oncogenic	K-Ras	G12C	and	G13C	via	covalent	drug	design	
by	
Chimno	Nnadi	
	
Abstract	
Ras	proteins	are	part	of	a	large	superfamily	of	small	monomeric	GTPases	that	act	as	molecular	
switches	to	regulate	cell	signaling.	Dysfunctional	Ras	signaling	is	implicated	in	30%	of	human	
cancers.	Of	the	3	protein	isoforms,	H-,	K-,	and	N-Ras,	K-Ras	is	the	most	commonly	mutated,	
particularly	at	residues	12	and	13.	K-Ras(G12C)	and	K-Ras(G13C)	are	acquired	mutations	in	lung	
and	colorectal	cancer,	which	are	among	the	most	common	and	deadly	malignancies	
worldwide.		Furthermore,	G12C	and	G13C	are	potentially	druggable	mutations	that	are	close	to	
the	switch	II	pocket	of	K-Ras.	Biochemical	studies	reveal	that	K-Ras(G13C)	is	a	fast	exchanging	
mutant,	with	a	potentially	destabilized	nucleotide	binding	pocket,	indicating	that	G13C	is	
structurally	different	from	G12C.		Despite	these	differences,	K-Ras(G12C)	and	K-Ras(G13C)	are	
both	amenable	to	covalent	drug	design	via	computational	and	empirical	screening	methods.	
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CHAPTER	1	
	
Establishment	of	K-Ras	as	an	important	drug	target	
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1.0	Gloss	
Oncogene	 specificity	 represents	 the	 future	 of	 cancer	 therapy.	 Targeted	 drug	
development	 rests	 on	 the	belief	 that,	 since	 cancer	 cells	 are	 very	 similar	 to	 self,	 promiscuous	
chemotherapy	 agents	 have	 a	 narrow	 therapeutic	 window	 and	 therefore	 selectivity	 is	
paramount	 to	 achieving	 cures.	 Moreover,	 certain	 classes	 of	 cancer	 are	 resilient	 to	 some	
targeted	 therapies	 that	 are	 upstream	 or	 downstream	 of	 the	 cellular	 signaling	 pathway.	 For	
example,	many	 K-Ras-driven	 cancers	 are	 resistant	 to	 treatment	with	 EGFR	 inhibitors	 such	 as	
cetuximab.	Also,	despite	the	availability	of	clinically	approved	inhibitors	of	RAF	and	MEK,	which	
are	 immediately	 downstream	 of	 Ras,	 these	 agents	 are	 ineffective	 on	 Ras-driven	 cancers.	
Efficacious	chemotherapy	regimens	rely	on	determining	the	oncogenic	driver	 through	genetic	
sequencing	and	treating	the	patients	for	the	identified	target.	
For	acquired	cysteine	mutations	in	cancer,	covalent	 inhibitors	are	an	effective	strategy	
to	 achieve	 oncogene	 specificity.	 Cysteine	 is	 the	 most	 nucleophilic	 amino	 acid,	 rendering	 it	
amenable	 to	 covalent	 labeling	 by	 electrophilic	 warheads.	 These	 cysteine-selective	 warheads	
can	allow	the	small	molecule	a	long	residence	time	within	a	nearby	binding	pocket	and	render	
the	protein	 target	 inactive	until	 it	 is	cellularly	 recycled.	Also	because	cysteine	 is	a	 rare	amino	
acid	with	a	prevalence	of	1.36%,	electrophilic	warheads	lead	to	more	selective	targeting.	
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1.1 Introduction	to	Ras	biology	
	
Figure	1.1:	Schematic	of	Ras	signaling	pathway	
Ras	proteins	 are	part	 of	 a	 large	 superfamily	of	 small	monomeric	GTPases	 (20-25	 kDa)	
that	 act	 as	 a	 molecular	 switch	 to	 regulate	 cell	 growth	 and	 proliferation.	 Ras	 is	 activated	 in	
response	 to	 growth	 factors	 binding	 to	 the	 receptor	 tyrosine	 kinases,	 stimulating	 the	
autophosphorylation	of	 tyrosine	 residues	on	 that	 receptor	which	bind	 to	 the	adaptor	protein	
GRB2	 to	 recruit	 SOS	 to	 activate	 Ras.	 Anchored	 by	 a	 lipid	 tail	 to	 the	 cellular	membrane,	 Ras	
cycles	between	an	inactive	GDP-bound	state,	and	an	active	GTP-bound	state,	in	response	to	the	
cellular	 environment.	 Ras	 activation	 is	 positively	 regulated	 by	 Son	 of	 Sevenless	 (SOS)	 and	
negatively	 regulated	by	GTPase-activating	protein	 (GAP),	with	 a	 key	 role	being	played	by	 the	
10:1	GTP:GDP	nucleotide	 ratio	within	 the	cell.	Ras	 signaling	 is	dysregulated	 in	30%	of	human	
cancers1,	rendering	it	the	most	common	oncogenic	driver.		
Ras	is	a	small	globular	protein	and	consists	of	a	core	G	domain	and	a	flexible	C-terminal	
tail	 that	 is	 farnesylated	 or	 geranylgeranylated	 and	 anchored	 to	 the	 cellular	membrane.	 Its	 G	
mTOR
AKT
PI3K
ERK
MEK
RAF
EGFR
KRas GDPAS
GDP
KRas GDPAS
GTP
EGF
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domain	 consists	 of	 several	 B-folds	 connected	 by	 a	 flexible	 P	 loop	 (residues	 10-17)	 and	 two	
flexible	switch	I-	(residues	30-40)	and	II	loops	(residues	60-76)	that	reside	above	the	nucleotide	
binding	pocket	and	the	allosteric	switch	II	pocket.	
Of	the	3	protein	isoforms,	H-,	K-,	and	N-Ras,	of	which	are	near	identical	at	the	G	domain,	
K-Ras	is	the	most	frequently	mutated,	particularly	at	residues	12	and	131,2.	Mutations	at	either	
codon	12	or	13	are	canonically	considered	to	prevent	productive	alignment	of	the	GAP	arginine	
finger,	which	completes	the	Ras	active	site3.		Although	these	codon	12	and	13	mutations	appear	
biochemically	 similar	 in	 their	 constitutive	 activation	 of	 Ras,	 several	 biochemical	 studies	 have	
shown	 unexpected	 differences	 between	 mutants,	 leading	 to	 allelic	 variation	 in	 K-Ras	 driven	
tumors4,5.	To	date,	no	biochemical	studies	have	identified	what	distinguishes	G12C	from	G13C.	
	
	
Figure	1.2:	Crystal	 structure	of	K-Ras	G12C	GDP	with	 switch	 II	 pocket	 inhibitor	 (green).	 The	
distance	between	G12C	(yellow)	and	G13C	(orange)	is	3.3	angstroms.	
	
	
	
Crystal	structure	of	K-Ras G12C	GDP	with	small	
molecule	079	(green).	 	The	distance	between	G12C	
(yellow)	and	G13C	(orange)	 is	3.3	angstroms.	
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1.2	G12C	oncogene	is	a	necessary	proof	of	principle	that	Ras	can	be	targeted	
K-Ras(G12C)	is	a	TGGà	TGT	transversion	mutation	that	resides	on	the	flexible	p-loop	of	
Ras.	K-Ras(G12C)	occurs	 in	40%	of	 lung	adenocarcinoma,	making	 it	a	highly	 important	 target.	
Despite	 the	 lack	 of	 biochemical	 data,	 selective	 targeting	 of	 K-Ras(G12C)	 has	 been	 achieved,	
driving	more	interest	in	the	biochemical	characterization	of	this	oncogene.	Ostrem	and	Peters	
demonstrated	 that	 K-Ras(G12C)	 can	 react	 irreversibly	 with	 covalent	 ligands	 that	 bind	 to	 a	
transient	pocket	under	the	switch-II	loop6	and	developed	G12C	inhibitors	using	fragment-based	
disulfide	tethering7.		
Through	 characterization	 of	 these	 early	 generation	 switch	 II	 pocket	 inhibitors,	 it	 was	
discovered	 that	G12C	still	participates	 in	nucleotide	cycling.	Therefore,	although	 the	 switch	 II	
pocket	 inhibitors	 bind	 preferentially	 to	 the	 GDP-bound	 state,	 they	 disrupt	 nucleotide	 cycling	
and	sequester	Ras	in	the	inactive	state	until	it	is	targeted	for	degradation.	It	was	shown	that	K-
Ras	mutants	such	as	K-Ras(G12C)	can	be	inhibited	by	an	allosteric	trapping	mechanism	in	order	
to	 kill	 patient	 derived	 K-Ras(G12C)	 lung	 adenocarcinoma	 cells6,8-10.	 	 Since	 then,	 Wellspring	
Biosciences	has	optimized	switch	 II	pocket	 inhibitors	 (ARS-1620)	 that	can	selectively	 target	K-
Ras(G12C)	within	the	cysteinome	and	shrink	K-Ras(G12C)	patient-derived	xenografts	in	mice10.	
Furthermore,	Amgen	has	developed	small	molecules	that,	in	phase	I	clinical	trials,	have	halted	
tumor	progression	for	patients	with	K-Ras(G12C)-driven	non-small	cell	lung	cancer11.	Therefore,	
the	 first	 K-Ras	 inhibitors	 are	 being	 used	 to	 treat	 patients,	 rendering	 the	 previously	
“undruggable”	target	druggable	and	proving	the	principle	that	targeting	Ras	is	instrumental	as	
therapy	for	Ras-driven	cancers.	
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1.3	G13C	is	an	unexplored	cancer	target	
K-Ras(G13C)	is	an	acquired	cancer	mutation	that	was	highlighted	in	a	2015	review	by	
Arkin	and	Dansen	as	a	feasible	yet	unexplored	target12.	K-Ras(G13C)	is	a	similarly	situated	
TGGà	TGT	transversion	mutation	that	occurs	in	cancer	patients,	that	is	just	one	amino	acid	
away	from	glycine	12.	The	cysteine	residue	is	surface	exposed,	and	resides	on	the	p-loop	nearer	
the	nucleotide	binding	pocket.	The	authors	speculated	that	preexisting	inhibitors	of	K-
Ras(G12C)	could	be	modified	into	G13C	inhibitors.		
K-Ras(G13C)	is	an	acquired	mutation	in	lung	and	colorectal	cancer13,	which	are	among	
the	most	common	and	deadly	malignancies	worldwide.	Every	year	about	100	patients	in	the	
U.S.	and	1,300	worldwide	die	of	K-Ras(G13C)-driven	metastatic	colorectal	cancer1.	The	G13C	
mutation	in	N-Ras	drives	myeloid	disorders	such	as	acute	myeloid	leukemia	(AML)	and	
myelodysplastic	syndrome13.	Prevalence	studies	in	the	United	States	in	2011	suggest	that	there	
are	presently	4000	colorectal	cancer	patients,	2000	patients	with	non-small	cell	lung	cancer,	
and	200	patients	with	AML	who	would	benefit	from	a	potent	Ras(G13C)	inhibitor14-17.	The	
design	of	covalent	G13C	inhibitors	is	critical	for	addressing	the	current	lack	of	therapy	for	these	
patients.	K-Ras(G13C)	could	be	amenable	to	allosteric	inhibition	utilizing	high	throughput	
screening	methods	such	as	covalent	docking,	disulfide	tethering,	and	mass	spectrometry	based	
electrophile	inhibition.	
There	has	been	very	little	biochemical	characterization	of	the	G13C	mutation	to	explain	
its	 differential	 oncogenicity	 and	 clinical	 phenotype	 to	 similar	 transforming	 mutations	 like	
G12C18.	 To	 date,	 there	 are	 no	 crystal	 structures	 of	 the	 G13C	 mutant	 to	 characterize	 this	
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oncogene.	Modeling	G13C	 into	 Ras	 presupposes	 that	 the	 cysteine	 rotamer	 is	 tilted	 from	 the	
switch	II	pocket,	like	its	G12C	predecessor.	Comparing	K-Ras(G12C)	and	K-Ras(G13D)	shows	that	
residue	 13	 is	 connected	 to	 the	 nucleotide	 binding	 pocket	 via	 a	 hydrogen	 bonding	 network,	
which	could	be	partially	disrupted	by	 the	mutation	 to	a	bulkier	mutant	 residue.	 	Biochemical	
data	 of	 G13D	 indicates	 that	 the	 codon	 13	 mutations	 may	 render	 these	 oncogenes	 as	 fast	
exchangers5.	Like	with	G12C,	studying	the	biochemical	basis	of	 the	oncogenicity	of	G13C	may	
be	instrumental	in	understanding	its	druggability.	
	
1.4	Optimization	of	covalent	drug	design	
The	 design	 of	 covalent	 inhibitors	 for	 known	 drug	 targets	 remains	 a	 difficult	 task.	 To	
avoid	hyper-reactive	 compounds,	most	high	 throughput	 screens	 (HTS)	 cautiously	 remove	any	
covalent	 compounds,	 barring	 canonical	 HTS	 as	 a	 screening	 method.	 Disulfide-tethering	 has	
been	successful	 for	 initial	development	and	proof	of	principle	of	G12C	 inhibitors	but	 requires	
multiple	 rounds	 of	 structure-activity-relationships	 to	 achieve	 a	 selective	 carbon-based	
electrophile	from	the	tethered	fragment.	Carbon-based	electrophile	 libraries	are	usually	small	
in	size	and	difficult	to	compare	in	terms	of	reactivity	to	various	targets.	With	the	advent	of	 in	
silico	 drug	 screening,	 covalent	 docking	 is	 furthermore	 also	 untested	 as	 an	 approach	 against	
difficult	 drug	 targets	 such	 as	 Ras.	 Most	 of	 the	 work	 described	 in	 the	 manuscript	 utilizes	 a	
medium-throughput	 mass	 spectrometry	 based	 method	 to	 screen	 and	 validate	 selective	
inhibitors	for	Ras.	
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1.5	Research	significance	
Through	 the	 research	 shown	 in	 this	 thesis,	 covalent	 docking	 is	 applied	 to	 the	
traditionally	undruggable	target	Ras	and	is	described	as	a	new	method	to	find	a	different	class	
of	 Ras	 binders.	 The	 vast	 structural	 and	 chemical	 data	 was	 utilized	 on	 G12C	 to	 predict	 new	
binders	of	the	switch	II	pocket	(S-IIP)	using	covalent	docking14,15,17,18.		Millions	of	commercially	
available	compounds	were	used	to	dock	acrylamide	fragments	to	K-Ras(G12C).		From	this	data	
arose	 a	 docking	 predicted	 class	 of	 G12C	 binders	 that	 accelerate	 nucleotide	 exchange.	 These	
small	 molecules	 are	 predicted	 covalent	 docking	 binders	 that	 destabilize	 Ras	 upon	 binding,	
achieving	nucleotide	exchange	via	fluorescence-based	methods.		These	binders	label	G12C	with	
favorable	 potency	 and	 selectivity.	 These	 results	 prove	 that	 DOCKovalent	 is	 an	 appropriate	
strategy	 to	 develop	 covalent	 inhibitors	 for	 canonically	 undruggable	 targets	 such	 as	 small	
GTPases.			
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CHAPTER	2	
	
Novel	K-Ras	G12C	Switch-II	Covalent	Binders	Destabilize	Ras	and	Accelerate	Nucleotide	
Exchange		
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2.0	Gloss	
The	success	of	targeted	covalent	inhibitors	in	the	global	pharmaceutical	industry	has	led	
to	a	resurgence	of	covalent	drug	discovery.	However,	covalent	inhibitor	design	for	flexible	
binding	sites	remains	a	difficult	task	due	to	lack	of	methodological	development.	To	avoid	
hyper-reactive	compounds,	most	high	throughput	screens	(HTS)	cautiously	remove	any	
covalent	compounds,	barring	HTS	as	a	screening	method.	DOCKovalent	is	a	novel	in	silico	
screening	method,	available	through	the	DOCK3.7	branch	of	the	well-tested	software	DOCK,	
that	allows	facile	screening	of	covalent	compounds	to	any	target	of	interest	with	a	reactive	
cysteine.		
In	the	current	decade,	a	series	of	small	molecule	inhibitors	of	K-Ras(G12C)	have	been	
designed	to	bind	to	a	transient	pocket	under	the	switch	II	loop	of	K-Ras(G12C)	called	the	switch	
II	pocket	(S-IIP).		Using	these	K-Ras(G12C)	inhibitors,	we	have	learned	that	K-Ras	mutants,	such	
as	K-Ras(G12C),	can	still	cycle	through	inactive	GDP	bound	state	and	can	be	actively	inhibited	by	
an	allosteric	trapping	mechanism	in	order	to	kill	patient	derived	K-Ras(G12C)	lung	
adenocarcinoma	cells.	This	immense	structural	and	chemical	data	can	be	utilized	to	predict	new	
inhibitors	of	K-Ras(G12C)	using	covalent	docking.	Here,	we	tested	DOCKovalent’s	ability	to	
target	a	traditionally	undruggable	protein,	such	as	K-Ras,	that	have	been	intractable	to	chemical	
inhibition	for	decades.	
We	drew	from	millions	of	commercially	available	compounds	to	dock	acrylamide	
fragments	to	K-Ras(G12C)	and	utilized	our	laboratory’s	intimate	structural	knowledge	of	the	S-
IIP	to	validate	results	from	covalent	docking	on	K-Ras(G12C)	Here,	we	compared	covalent	
docking	to	empirical	electrophile	screening,	against	the	highly	dynamic	target	K-Ras(G12C).	
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While	the	overall	hit-rate	of	both	methods	was	comparable,	we	were	able	to	rapidly	progress	a	
docking	hit	to	a	potent	irreversible	covalent	inhibitor	that	modifies	the	inactive,	GDP-bound	
state	of	K-Ras(G12C).	Hydrogen-deuterium	exchange	mass	spectrometry	was	used	to	probe	the	
protein	dynamics	of	compound	binding	to	the	switch-II	pocket	and	subsequent	destabilization	
of	the	nucleotide-binding	region.	SOS-mediated	nucleotide	exchange	assays	showed	that,	
contrary	to	prior	switch-II	pocket	inhibitors,	these	compounds	appear	to	accelerate	nucleotide	
exchange.	This	study	highlights	the	efficiency	of	covalent	docking	as	a	tool	for	the	discovery	of	
chemically	novel	hits	against	challenging	targets.	Upon	developing	covalent	docking	with	K-Ras	
(G12C),	the	methodology	can	be	extended	to	G13C,	an	understudied	mutant	with	an	unmet	
clinical	need.		
	
2.1	Introduction	
Covalent	drugs	have	long	been	part	of	the	pharmaceutical	medicine,	from	inadvertent	
ones	like	the	P2Y12	drugs	to	beta-lactams	to	fosfomycin	to	aspirin19.		Despite	this,	covalent	
inhibitors	were	specifically	avoided	by	the	pharmaceutical	industry	until	recently,	due	to	
concerns	of	off-target	toxicity.20,21	The	recent	approval	of	afatinib,	ibrutinib,	and	osimertinib,	
which	target	non-conserved	cysteines	in	the	ATP	binding	site	of	kinases,	has	accelerated	interest	
in	covalent	drug	discovery.	These	irreversible	kinase	inhibitors	were	developed	using	potent	
reversible	ATP	binding-site	ligands	as	a	starting	scaffold,	which	are	then	endowed	with	an	
acrylamide-based	electrophile	(“warhead”).	This	approach	allows	the	use	of	a	mild	electrophile,	
while	relying	on	the	potent	reversible	binding	affinity	of	the	inhibitor	to	“present”	the	warhead	
to	the	active	site	cysteine.22		
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A	much	more	challenging	target	is	exemplified	by	K-Ras	which	has	no	high	affinity	
reversible	ligands	except	the	endogenous	GDP/GTP	nucleotides	(KD	~	pM).23	K-Ras	is	a	small	G	
protein	that	acts	as	molecular	switch	to	activate	mitogenic	signaling	pathways	in	the	presence	
of	growth	factors.	Somatic	KRAS	mutations,	including	G12C	induce	resistance	to	GTPase	
activating	proteins	(GAPs)	and	impair	intrinsic	GTP	hydrolysis.	This	results	in	constitutively	
elevated	levels	of	K-Ras-GTP	and	leading	to	aberrant	cell	growth.	Approximately	25%	of	lung	
adenocarcinomas	harbor	KRAS	mutations,	including	40%	that	result	in	G12C	substitutions.		In	
order	to	discover	the	first	K-Ras(G12C)	allosteric	inhibitor,	a	fragment-based	tethering	screen	
was	used.6	Tethering	is	carried	out	with	reversible	covalent	disulfides	to	identify	
thermodynamically	favorable	interactions	with	the	protein	target.		Covalent	bond	formation	in	
this	screen	can	be	attenuated	with	a	stringency	factor	(usually	by	adjusting	the	levels	of	2-
mercaptoethanol).7	Following	hit	discovery,	further	medicinal	chemistry	is	required	to	convert	
disulfide	hits	from	the	screen	to	carbon-based	electrophiles	that	are	compatible	with	the	
cellular	environment.	This	conversion	can	be	challenging.			
The	optimization	of	the	K-Ras(G12C)	irreversible	ligands	has	yielded	two	important	
insights:	(1)	The	determination	of	multiple	co-crystal	structures	revealed	a	highly	flexible	ligand	
binding	pocket	(termed	switch-II	pocket;	S-IIP)	beneath	the	switch-II	loop;	and,	(2)	even	the	best	
irreversible	inhibitors	show	only	weak	(>200µM)	binding	in	the	absence	of	the	warhead.6,8-10	
These	findings	were	initially	thought	to	limit	the	druggability	of	K-Ras(G12C).	Recently	however,	
potent	on-target	inhibition	of	K-Ras(G12C)	has	been	validated	extensively.	6,8-10	These	molecules	
allosterically	trap	K-Ras(G12C)	in	the	inactive	GDP-bound	state	by	preventing	SOS-mediated	
nucleotide	exchange.	Covalent	inhibition	by	modification	of	G12C	allows	oncogene	specific	
 13	
inhibition,	sparing	the	wild-type	protein	from	inhibition,	which	is	predicted	to	contribute	to	the	
ultimate	therapeutic	index	in	patients.	
Recognizing	the	growing	importance	of	covalent	drug	discovery	and	the	unique	features	
of	flexible	protein	targets	like	K-Ras(G12C),	we	set	out	to	compare	one	empirical	screening	
approach	and	a	virtual	screening	approach	to	discovering	new	K-Ras(G12C)	binders.		There	is	
little	information	on	how	covalent	electrophile	libraries	fare	in	comparison	to	other	screening	
approaches.24	We	tested	a	fragment-based	acrylamide	library	using	mass	spectrometry	in	
conjunction	with	covalent	virtual	screening	via	DOCKovalent,	a	structure-based	virtual	screening	
algorithm	that	predicts	covalent	ligand	binding	to	a	target	receptor.25,26	Unlike	disulfide	
tethering,	the	latter	two	approaches	directly	screen	compounds	containing	the	reactive	
warheads	(e.g.	acrylamides)	for	optimal	ligand-receptor	geometry,	thereby	simplifying	
downstream	medicinal	chemistry.		
Simulating	protein	flexibility	is	a	major	challenge	for	molecular	docking.27	K-Ras	is	a	
highly	dynamic	target.	Many	of	the	available	24	inhibitor-bound	K-Ras(G12C)	crystal	structures	
that	were	available	at	the	start	of	this	study	showed	altered	pocket	topology	due	to	switch-II	
loop	flexibility	and	induced	fit	around	structurally	diverse	ligands.	Accounting	for	flexibility	is	a	
challenge	in	docking	and	many	methods	have	been	explored	in	the	literature.28-36	However,	
these	methods	can	often	reduce	predictive	success	by	increasing	false	positives,	demonstrated	
in	retrospective	calculations	that	confirm	the	loss	of	enrichment	of	known	ligands	over	
decoys.37-42	Here,	we	utilize	the	enrichment	of	a	known	ligand	as	the	selection	criteria	for	
picking	the	best	receptor	structure	for	molecular	docking.	
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Previously,	DOCKovalent	was	used	to	discover	reversible	covalent	inhibitors.	This	is	the	
first	prospective	study	using	DOCKovalent	to	find	irreversible	inhibitors	of	a	target,	specifically	K-
Ras(G12C).	We	show	that	covalent	docking	is	comparable	to	screening	a	small	library	of	
electrophilic	fragments	in	terms	of	hit	rate	and	off-target	reactivity.	We	find	that	covalent	
docking	in	combination	with	orthogonal	biophysical	methods	such	as	thermal	stability	assays	
and	hydrogen-deuterium	exchange	mass	spectrometry	can	successfully	identify	novel	
irreversible	compounds	with	favorable	potency	and	specificity	for	K-Ras(G12C).	Furthermore,	
covalent	docking	produced	compounds	that	are	structurally	diverse	and	which	exert	
dramatically	different	biochemical	effects	from	compounds	discovered	using	disulfide	tethering	
approaches	previously	applied	to	the	same	target.	
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Figure	2.2.1.	Structural	alignment	of	24	ligand-bound	monomers	of	K-Ras(G12C).		The	PDB	IDs	
for	the	individual	structures	can	be	found	in	Table	2.10.1.	 	
Switch II
Switch I
GDP
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2.2	Docking	guided	template	selection	
Structures	of	twenty-four	distinct	monomers	of	K-Ras(G12C)	in	complex	with	a	covalent	
compound	were	available	for	docking	(Table	2.10.1).		Superimposing	all	of	the	different	
structures	illustrates	the	significant	flexibility	of	the	switch	II	region	and	the	caveats	of	docking	
to	a	static	structure	(Figure	2.2.1).		
In	order	to	select	a	suitable	structure	for	the	docking	screen,	we	first	attempted	to	
computationally	recapitulate	the	previous	empirical	tethering	screen	results	from	Ostrem	et	al.6	
The	original	tethering	library	of	480	compounds	has	since	doubled	in	size.	We	covalently	docked	
this	library	of	960	disulfide	containing	compounds	as	a	more	stringent	test	for	enriching	known	
binders.	We	identified	the	best	candidate	for	docking	(PDB:	4M1S	chain	B)	as	the	structure	that	
enriches	for	compound	6H05,	the	best	reported	K-Ras(G12C)	tethering	hit	(94	±	1%	modification	
of	K-Ras(G12C),	Figure	2.2.2).	Compound	6H05	ranked	15/960	for	this	structure	(top	1.5%).	The	
docking	pose	placed	the	p-chloro-benzene	in	the	hydrophobic	region	of	S-IIP	(Figure	2.2.2b)	as	
observed	in	the	co-crystal	structure	of	a	6H05-analogue	in	complex	with	K-	Ras(G12C)	(PDB:	
4LUC).		
We	then	used	4M1S	chain	B	to	dock	a	test	set	of	110	previously	synthesized	
vinylsulfonamide-based	compounds	in	structure-activity	relationship	(SAR)	efforts	to	find	more	
potent	S-IIP	binders.		Vinylsulfonamide	13,	the	crystallographic	ligand	in	4M1S,	ranked	4	out	of	
this	library,	closely	recapitulating	the	crystallographic	binding	mode	(1.35Å	r.m.s.d.;	Figure	
2.2.2c-d).	These	results	in	which	both	disulfide	hits	and	carbon	based	electrophiles	were	
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correctly	selected	by	the	program	encouraged	us	to	use	4M1S	chain	B	for	a	large-scale	virtual	
screen	against	K-Ras(G12C).		
	
	
Figure	2.2.2.	Docking	pose	of	disulfide	 tethering	hit,	6H05	a.	 Structure	of	disulfide	 tethering	
hit,	6H05.	b.	Docking	pose	of	6H05	(blue)	in	docking	model	(PDB:	4M1S	chain	B)	aligned	to	co-
crystal	 structure	 of	 tethering	 analogue	 (magenta)	 (PDB:	 4LUC).	 c.	 Structure	 of	 ligand	 13.	 d.	
Docking	pose	of	13	(blue)	aligned	to	co-crystal	structure	of	13	(magenta;	PDB:	4M1S	chain	B).	
	 	
Cl
S
N
O
O
H
N
S
S NH
6H05 13
a
b d
c H
N
N
O
N
H
S
O
O
Cl Cl
 18	
2.3	Covalent	library	design	and	docking		
Prior	efforts	to	generate	K-Ras(G12C)compounds	have	relied	on	disulfide-tethering	as	a	
starting	point	to	generate	the	high	affinity	reversible	binding	element.6,7	However,	conversion	of	
a	disulfide	to	a	carbon-based	electrophile	requires	iterative	optimization	of	electrophile	
geometry	and	linker	length	to	successfully	engage	the	target	cysteine.		DOCKovalent	directly	
screens	carbon	electrophiles	and,	in	doing	so,	optimizes	ligand	orientation	and	electrophile	
position.	
In	addition	to	electrophile	orientation,	the	tuning	of	electrophile	reactivity	also	
represents	a	challenge	to	the	design	of	covalent	inhibitors.43	Overly	reactive	electrophiles	may	
have	promiscuous	off-target	effects,	while	non-reactive	electrophiles	may	not	be	able	to	form	a	
covalent	bond	with	the	target.	Unsubstituted	acrylamides	are	found	in	clinically	approved	
agents	and	are	considered	mild	electrophiles	that	react	with	nucleophilic	cysteines	when	
receptor	and	ligand	geometry	is	optimized.44		
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	Figure	 2.3.	 Analysis	 of	 ligand	 diversity	 in	 DOCKovalent	 and	 empirical	 screening	 libraries	 a.	
Summary	of	screening	methods	for	covalent	 ligand	discovery.	b.	Pairwise	Tanimoto	scores	for	
each	library	were	generated	using	ECFP4	fingerprints	and	clustered	into	a	50-bin	histogram.		
	
To	computationally	explore	a	diverse	set	of	acrylamides,	we	constructed	two	virtual	
libraries	based	on	fragment-like	(xLogP	<=	3.5,	Molecular	Weight	<=	250,	Number	of	rotatable	
bonds	<=	5)	primary	(N=28,350)	and	secondary	(N=31,949)	aliphatic	amines	(Figure	2.3a).45	
Pairwise	Tanimoto	scores	for	all	the	compounds	in	the	DOCKovalent	virtual	library,	the	
acrylamide	physical	library	and	the	disulfide-tethering	library	showed	increased	ligand	diversity	
in	the	covalent	docking	library	(Figure	2.3b).	Acrylamides	were	generated	in	silico	from	the	
amine	building	blocks.	The	ligands’	conformations,	stereoisomers,	and	protonation	states	were	
then	pre-computed	to	allow	for	rapid	docking.	
In	K-Ras(G12C)crystal	structures,	cysteine	12	usually	samples	two	favored	rotamers:	(1)	
facing	the	nucleotide	binding	site,	often	seen	in	apo	structures;	and,	(2)	towards	the	switch-II	
pocket	observed	in	ligand-bound	G12C	structures.	These	rotamers	have	been	observed	in	
structures	with	different	space	groups	and	unit	cell	dimensions,	suggesting	that	they	are	not	
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predetermined	by	crystallographic	conditions.	Using	DOCKovalent	3.625,	we	docked	the	two	
libraries	to	both	putative	rotamers	of	cysteine	12	(χ1=-169.9°,	-69.8°)	in	4M1S	chain	B.	The	top	
500	compounds	(top	1.5%	of	each	library)	from	each	screen	were	manually	inspected	and	
filtered	for	criteria	that	are	not	assessed	by	the	docking	energy	function	such	as	internal	ligand	
strain,	unlikely	protonation	states,	correct	representation	of	the	ligand	in	the	docking	pose,	and	
synthetic	accessibility	and	commercial	availability	of	the	amine-based	building	blocks.		
	
2.4	Docking	and	empirical	screening	show	similar	hit	rates	
Twenty-nine	compounds	from	the	covalent	docking	library	were	selected,	synthesized	
and	experimentally	tested	against	Cys-light	K-Ras(G12C)	(a	truncated	construct,	residues	1-169,	
that	contains	only	a	single	cysteine	at	position	12).	For	the	empirical	screening	set,	we	screened	
an	acrylamide	subset		
Table	2.4.2.	Results	of	mass-spectrometry	based	screen	of	acrylamide	library	and	DOCKovalent	
library.		
	
	
Electrophile 
Library!
DOCK-
ovalent!
Library Size! 94! 60,299!
MW! 150-300! <300!
Assayed! 63! 29!
Hits! 9! 2!
Nonspecific 
Hits!
7! 1!
Nonspecific!
compounds!
22! 7!
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(N=62)	of	a	carbon	electrophile	library	(Table	S2-3).	To	assess	off-target	reactivity,	we	
also	tested	compound	engagement	to	full	length	K-Ras(WT)	1-189,	which	contains	additional	
cysteines	including	a	flexible	C-terminal	C185.	Overall,	the	two	libraries	showed	comparable	hit	
rates	(7-15%)	and	reactivity	profile	(Table	2.4.2).		The	electrophile	library	contained	more	
promiscuous	acrylamides	overall	than	the	docking	library	(Table	2.4.2).	We	highlight	two	
examples	of	acrylamide	hits	1-4	from	each	library	that	are	moderately	reactive	to	both	G12C	
and	the	control,	K-Ras(WT)1-189	(Figure	2.4.1a-b).		
We	chose	to	pursue	acrylamide	1	from	the	covalent	docking	library	based	on	its	high	
reactivity	to	K-Ras(G12C)	(Figure	2.4.1a-b),	its	novelty	compared	to	known	K-
Ras(G12C)binders6,	and	the	chemical	tractability	of	its	scaffold.	The	proline	linker	offers	only	a	
few	rotatable	bonds,	which	may	sample	a	few	conformationally	constrained	orientations	to	
produce	the	final	binding	pose	in	which,	the	linker	rigidly	inserts	the	naphthalene	into	the	
hydrophobic	S-IIP	(Figure	2.4.1c).	Analysis	of	the	docking	poses	of	the	binders	revealed	that	
only	compound	1	showed	the	potential	for	hydrogen	bond	formation,	specifically	to	R67.	We	
also	investigated	the	potential	binding	pose	of	compound	1	using	DOCK3.6	(reversible	docking),	
which	does	not	constrain	the	covalent	bond.		The	pose	produced	by	DOCK3.6	recapitulates	the	
DOCKovalent	pose	with	only	a	slight	rotation	of	the	electrophile	amide	bond	(Figure	2.4.2).	
	
	
 22	
	
Figure	2.4.1.	Docking	results	and	poses	a.		The	percent	modification	of	K-Ras(WT)	1-189	vs	Cys-
light	K-Ras(G12C)1-169	by	compounds	in	the	docking	library	(blue)	or	the	empirical	library	(red)	
b.	 Potential	 hits	 from	each	 library.	 c.	 DOCKovalent	 pose	of	 compound	1	 and	d.	 compound	2	
bound	to	K-Ras(G12C).		
	
	
	
Figure	 2.4.2	 Surface	 representation	 of	 K-Ras(G12C)	 with	 the	 docking	 pose	 of	 compound	 1	
depicting	the	interior	of	the	S-IIP.	
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Table	2.5.	Compound	1	analogue	structure-activity-relationship.	Percentages	represent	adduct	
formation	 to	 Cys-light	 K-Ras(G12C)	 1-169	 or	 K-Ras(G12C)	 1-189	with	 200uM	 compound	 after	
24h,	25°C	by	mass	spectrometry.	Percentages	are	an	average	of	three	experiments.	
	
	
	
	
Figure	2.5.1.	DOCK	and	DOCKovalent	poses	are	not	recapitulated	 in	crystallographic	pose	a.	
DOCK	pose	 (green)	 and	DOCKovalent	 pose	 (cyan)	 of	 compound	1	 overlay	 closely	with	 only	 a	
slight	 rotation	 of	 the	 amide	 bond	 in	 the	 pyrrolidine-2-carboxamide	 linker.	 b.	 Alignment	 of	
DOCKovalent	pose	of	 compound	1	 (cyan;	protein	 in	 slate)	 to	 crystal	 structure	of	K-Ras(G12C)	
(white;	PDB:	6ARK)	in	complex	with	compound	10	(green).	
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2.5	Docking	hit	could	be	optimized	to	a	selective,	potent,	binder	
We	used	the	docking	model	in	combination	with	commercially	available	building	blocks	
to	expedite	compound	optimization	(Table	2.5).	By	contrast,	previous	efforts	starting	with	a	
disulfide	tethering	hit	required	extensive	medicinal	chemistry	to	convert	the	disulfide	fragments	
to	acrylamides6.	In	addition	to	reacting	to	the	G12C	residue,	acrylamide	1	exhibited	nonspecific	
labeling	of	the	C-terminal	cysteine	of	K-Ras(WT)	(Table	2.5)	which	was	a	feature	important	to	
address	during	the	chemical	optimization	of	the	scaffold.	The	docking	model	(Figure	2.5.1)	
suggested	that	hydrophobic	substitutions	around	the	naphthalene	moiety	might	be	tolerated.	
Indeed,	the	testing	of	a	series	of	substitutions	led	to	the	discovery	of	6-bromo-naphthalene	
modification	with	improved	labeling	of	85%	(200uM;	24h;	25°C).	Structure-activity-relationship	
analysis	of	acrylamide	1	also	suggested	that	alterations	to	the	proline	linker	fine-tuned	
acrylamide	specificity	and	compound	affinity	(Table	2.5).	For	example,	substitution	of	D-proline	
for	the	L-proline	abrogated	G12C-specific	reactivity	but	maintained	comparable	labeling	to	the	
wild	type	K-Ras.	Additional	modification	of	the	proline	linker	to	cis-3-hydroxy-L-proline	led	to	
the	most	potent	acrylamide	10	(Figure	2.5.2a).		The	proline	modification	substantially	improved	
the	potency	of	10,	which	was	able	to	reach	78%	labeling	at	25uM	(Figure	2.5.2b).	Compound	10	
also	does	not	rely	on	the	binding	affinity	of	a	chemically	reactive	phenol	from	the	early	
generation	G12C	inhibitors,	which	represents	an	improvement	in	the	druglikeness	of	the	
chemical	scaffold.6,8		
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Figure	2.5.2.	Compound	10	destabilizes	K-Ras(G12C)	a.	Structures	of	compound	10	and	switch-
II	 inhibitor	 11.	 b.	 Percentages	 represent	 adduct	 formation	 to	 K-Ras	 constructs	 with	 25uM	
compound	over	24h,	25°C.	Sos-catalyzed	exchange	of	apo	and	compound-labeled	K-Ras(G12C)	
GDP	with	c.	BODIPY-FL-GDP	and	d.	BODIPY-FL-GTP	fluorescence	intensity	was	monitored	over	
time.	e.	Co-crystal	structure	of	10	(blue)	and	K-Ras(G12C)	GDP	(grey).	f.	Fo-Fc	omit	map	(grey	
mesh,	 2.0σ)	 of	 10.	 g.	 Cartoon	 representation	 of	 p-loop	 (slate),	 Cys12,	 and	 10	 (blue)	 with	
indicated	residues	that	make	hydrophobic	contacts	with	10	in	nearby	symmetry	mate	(white).	
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This	compound	only	labels	G12C	in	the	GDP-bound	state	and	does	not	label	endogenous	
cysteines	in	the	full	K-Ras4B	construct	(Figure	2.5.2b).		Compound	10	does	not	react	with	the	
active	state	of	Ras,	as	indicated	by	the	lack	of	binding	to	K-Ras(G12C)	GppNHp.	This	is	
comparable	to	results	using	a	previously	reported	switch	II	inhibitor,	compound	11	(Figure	
2.5.2a),	that	was	discovered	through	tethering.		
	
2.6	New	compound	accelerates	nucleotide	exchange		
We	examined	the	effect	of	these	compounds	on	the	nucleotide	exchange	rate	of	K-Ras	in	
vitro	using	a	fluorescence	nucleotide	exchange	assay.	SOS-catalyzed	exchange	of	BODIPY-GDP	
and	BODIPY-GTP	in	K-Ras(G12C)	GDP	constructs	showed	increased	exchange	of	both	fluorescent	
nucleotides	in	the	presence	of	compound	10	but	not	with	11	(Figure	2.5.2c-d).	Acrylamide	
inhibitors	of	K-Ras(G12C)	have	previously	exhibited	favored	GDP	binding	due	to	strong	steric	
clash	with	the	γ-phosphate	of	GTP	as	well	as	disrupting	key	side	chain	interactions	that	interact	
with	the	terminal	phosphate.6,8	The	mass	spectrometry	experiments	show	that	compound	10	
prefers	to	bind	inactive	K-Ras(G12C)as	well.	After	binding	G12C,	compound	10	may	destabilize	
the	switch	I	region	or	phosphate	loop	and	cause	increased	nucleotide	cycling.		
	
2.7	Structural	determination	of	K-Ras(G12C)	in	complex	with	compound	10	
We	attempted	to	crystallize	Cys-light	K-Ras(G12C)	bound	to	compound	10	using	various	
methods	including	co-crystallization,	soaking,	and	seeding	using	pre-formed	crystals	from	a	
 27	
different	S-IIP	inhibitor.	Co-crystallization	experiments	were	successful,	and	we	determined	a	
1.75Å	co-crystal	structure	of	K-Ras(G12C)	covalently	bound	to	compound	10	(PDB:	6ARK).	
Crystallographic	evidence	reaffirms	that	the	molecule	is	bound	to	G12C	and	suggests	that	the	
ligand	interaction	to	the	protein	is	weak	(Figure	2.5.2e-g).	Well	defined	electron	density	
confirmed	compound	10	covalently	bound	to	G12C,	however	it	did	not	occupy	the	switch	II	
pocket	in	the	crystal	structure	but	rather	was	making	nearby	van	der	Waals	interactions	with	
the	α2	(switch-II)	helix	of	a	nearby	symmetry	mate	(Figure	2.5.2f;	Fo-Fc	at	2.0σ).	This	
characteristic	is	not	unique	to	compound	10,	as	other	early	stage	switch	II	binders	were	
crystallized	with	binding	poses	outside	the	ligand-binding	site.	It	is	unlikely	that	the	
crystallographic	pose	represents	the	in-solution	binding	pose.	The	crystallographic	pose	may,	
however,	indicate	that	10	is	not	stable	in	the	S-IIP	site	following	the	formation	of	the	covalent	
bond	to	G12C.	
	
2.8	Compound	binding	destabilizes	K-Ras	
In	order	to	assay	the	protein	dynamics	of	K-Ras	bound	to	compounds	10	and	11,	we	
utilized	hydrogen-deuterium	exchange	mass	spectrometry	(HDX-MS;	Figure	2.8).	HDX-MS	is	a	
technique	that	measures	the	exchange	rate	of	amide	hydrogens	with	deuterated	solvent,	and	
since	the	main	determinant	of	amide	exchange	is	their	involvement	in	secondary	structure,	it	is	
an	excellent	probe	of	protein	dynamics.46,47	Experiments	were	carried	out	for	five	time	points	of	
H/D	exchange	(0.3,	3,	30,	300,	and	3000	s)	in	deuterated	buffer	at	pH	7.5.	HDX-MS	data	of	K-
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Ras(G12C)	bound	to	GDP	were	consistent	with	previously	published	reports,	confirming	the	
flexibility	of	both	the	switch	I	and	switch	II	loops.48		
	
	
Figure	2.8.1.	Hydrogen-deuterium	exchange	on	compound	10-bound	K-Ras(G12C)	a.	Relative	
hydrogen-deuterium	exchange	differences	between	compound	11-bound	K-Ras(G12C)	GDP	and	
apo	 K-Ras(G12C)	 GDP	 represented	 on	 co-crystal	 structure	 with	 compound	 11	 (PDB	 4M21).	
Dashed	 lines	 represent	 disordered	 regions	 b.	 Hydrogen-deuterium	 exchange	 differences	
between	compound	10-bound	K-Ras(G12C)	GDP	and	apo	K-Ras(G12C)	GDP	represented	on	the	
docking	pose	c.	Thermal	stability	assay	on	K-Ras(G12C)	with	compounds	10	and	11	and	d.	the	
T50	melting	temperatures.	
	 	
40 50 60 70
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
Temperature (°C)N
or
m
al
ize
d 
Fl
uo
re
sc
en
ce
G12C
G12C-10
G12C-11
S-II
>6%
<-6%
N.D.
-6 to   
  6%
% Deuteration
b
c
a
d
Difference between K-Ras(G12C) GDP and
K-Ras(G12C) GDP bound to Compound 11
Difference between K-Ras(G12C) GDP and
K-Ras(G12C) GDP bound to Compound 10
KRas GDPKRas
GDP
KRas
GDPSM
C12
C12
S-II S-I
S-I
Switch-II Switch-I
GDP
Interswitch
Region
GDP
Interswitch
RegionSwitch-II Switch-I
K-RasG12C
T50 
(95% Confidence) 
No compound 59.46°C
(59.33 - 59.58°C)
10
54.76°C
(54.64 - 54.88°C)
57.04°C
(56.89 - 57.18°C) 11
IR
IR
β1β2 β2 β1 
α3
β4
α4
β5
β6
 29	
	
	
Figure	2.8.2.	Thermal	stability	assay	on	compound	12	a.	Structure	of	compound	12.	b.	Thermal	
stability	assay	of	K-Ras(G12C)	labeled	with	compound	12	and	c.	the	T50	melting	temperature.	
Numerous	changes	in	H/D	exchange	were	observed	when	comparing	KRas(G12C)	GDP	in	
the	presence	and	absence	of	compounds	10	or	11.	Compound	11	is	a	confirmed	switch	II-binder	
(PDB:	4M21),	and	showed	decreased	exchange	in	the	interswitch	region	(IR)	composed	of	β2	
and	β3	as	well	as	the	switch	II	region	(Figure	2.8.1).	Comparatively,	10	also	showed	decreases	in	
exchange	in	the	IR	and	switch	II	regions,	and	increased	exchange	of	the	α3	and	α4	helices.			
To	assess	whether	compound	binding	to	K-Ras	was	in	a	favorable	conformation	after	
covalent	bond	formation,	we	used	a	thermal	stability	assay	which	measures	the	thermal	shift	
associated	with	compound	binding.	Recent	studies	have	demonstrated	that	compound	
stabilization	correlates	with	increased	potency.49	For	example,	compound	12	in	Ostrem	et	al.	
showed	marked	improvement	in	labeling	of	G12C	(100%	labeling	using	10uM	compound)6	and	
also	thermal	stabilization	of	K-Ras(G12C)	by	4°C	(Figure	2.8.2).	Compounds	10	and	11	induce	
4.7	and	2.4°C	destabilization	of	K-Ras	respectively	(Figure	2.8.1c-d),	indicating	they	may	be	
destabilizing	core	regions	of	the	protein	upon	binding.		For	compound	10	this	is	consistent	with	
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the	increases	in	H/D	exchange	observed	throughout	large	regions	of	the	protein.	Further	
structure-activity-relationships	will	be	critical	to	increase	the	potency	of	compound	10.	
	
2.9	Conclusion	
This	is	the	first	prospective	application	of	DOCKovalent	towards	finding	an	irreversible	
covalent	inhibitor.	From	the	results	of	this	study,	covalent	docking	appears	to	significantly	
accelerate	early	hit	discovery	against	a	very	challenging	and	flexible	target.	The	initial	screen	
revealed	2	of	29	compounds	could	react	with	K-Ras(G12C)	a	7%	success	rate.	These	results	were	
comparable	to	an	empirical	electrophile	library	screen.	DOCKovalent	does	not	take	into	account	
the	variability	of	the	acrylamide	warhead	electronics	at	the	covalent	attachment	point.25	It	is	
therefore	encouraging	that	it	was	able	to	rank	two	fragments	that	successfully	engage	the	
protein	without	being	overly	promiscuous.	Future	incorporation	of	warhead	reactivity	or	
covalent	reversible	warheads	may	further	reduce	false	positive	hits	from	docking.27	Although	
the	hit	rates	were	not	as	high	as	previous	covalent	docking	campaigns27,	the	success	rate	was	
still	comparable	to	typical	non-covalent	virtual	screening	hit	rates.		
From	the	docking	hit,	we	generated	a	chemically	distinct	G12C	inhibitor	which	lacked	the	
chemically	reactive	phenol	from	the	original	scaffold.6,8	Early	generation	switch	II	pocket	
inhibitors	gained	potency	through	modifications	that	increased	binding	to	the	switch-II	pocket	
region.	The	cis-3-hydroxy-L-proline	linker	used	in	this	study	increased	the	potency	8-fold,	
demonstrating	that	high	affinity	linker	modifications	can	enhance	scaffold	binding.	
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The	performance	of	DOCKovalent	is	greatly	dependent	on	the	input	structure.	K-Ras	is	a	
highly	flexible	target,	particularly	in	the	switch	I	and	II	loops,	which	are	integral	to	the	ligand-
binding	site.	This	study	was	performed	using	ligand	enrichment	of	fragment	disulfides	and	
vinylsulfonamides	on	24	co-crystal	structures	of	K-Ras	inhibitors.	However,	the	recent	K-
Ras(G12C)	inhibitor	ARS-853	binds	to	an	extended	pocket,	forming	three	hydrogen	bonds8	and	
may	not	have	ranked	highly	in	the	original	docking	screen	on	the	smaller	K-Ras	co-crystal	
structures.	In	addition	to	ligand	enrichment,	ensemble	docking	with	consensus	ranking	on	
distinct	structural	subsets	may	improve	covalent	ligand	design	against	highly	flexible	targets.	Or,	
perhaps,	a	flexible	receptor	procedure,	which	accounts	for	crystallographically	observed	
alternative	states	of	side	chains	and	loops,	could	be	incorporated	into	covalent	docking	to	
improve	the	results.27	
This	study	further	demonstrates	that	the	switch	I	and	switch	II	loops	are	tightly	
coordinated.	The	S-IIP	binders	can	communicate	across	the	loops	to	affect	nucleotide	
recognition	and	Ras	activity.	Especially	in	flexible	proteins,	the	empiric	validation	of	ligand	
binding	needs	to	consider	thermodynamic	stability	of	the	ligand-protein	interaction.	The	
thermal	stability	assay	demonstrated	that	compound	10	was	thermodynamically	destabilizing	to	
the	protein.	This	destabilizing	property	was	consistent	with	increased	H/D	exchange	and	also	
with	increased	SOS-catalyzed	nucleotide	exchange	of	both	GDP	and	GTP.	Covalent	inhibitors	
may	have	destabilizing	noncovalent	interactions	with	the	protein	after	covalent	adduct	
formation.34	Thus,	the	thermal	stability	assay	may	prove	useful	as	a	counter-screening	method	
to	measure	the	stabilizing	noncovalent	interactions	during	small	molecule	optimization.	This	
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assay	may	be	particularly	useful	for	classifying	K-Ras	switch	II	compounds	as	allosteric	inhibitors	
or	potential	nucleotide	state	destabilizers.		
In	this	study,	we	describe	a	novel	small	molecule	that	destabilizes	K-Ras	and	behaves	like	
no	other	switch	II	pocket	binder	in	its	unique	ability	to	accelerate	SOS-mediated	nucleotide	
exchange.	We	believe	this	will	help	development	of	novel	allosteric	inhibitors	of	K-Ras	that	can	
be	used	to	study	aspects	of	nucleotide	exchange.	
	
2.10	Methods	
Covalent	docking	
Covalent	docking	was	performed	using	DOCKovalent	as	described	and	implemented	in	
DOCK3.6.25	The	covalent	bond	parameters	were	set	to:	length=1.8Å,	bond	angles=109.5°±10°	(in	
2.5°	steps).		
Protein	expression	and	purification	
K-Ras	constructs	were	purified	as	previously	specified.6	Briefly,	His6-tagged	recombinant	
bacterial	human	K-Ras	(isoform	2,	residues	1-169),	K-Ras	Cys-light	(isoform	2,	residues	1-169,	
C51S/C80L/C118S),	K-Ras	(isoform	2,	residues	1-	189)	were	transformed	into	Escherichia	coli	
(BL21	(DE3))	for	expression.	K-Ras(G13C)	was	introduced	into	each	vector	using	a	QuikChangeTM	
PCR	protocol.	Protein	cultures	were	grown	in	TB	with	kanamycin	at	37˚C.	Upon	an	optical	
density	(OD600)	reached	0.5-0.6,	were	induced	at	18˚C	with	120mg	IPTG	and	expressed	over	18	
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hours.	The	cells	were	pelleted	at	4,5000	rpm,	resuspended	in	lysis	buffer	(500	mM	NaCl,	20	mM	
TRIS	pH	8.0,	5	mM	imidazole,	1	tablet	of	Roche	cOmplete	EDTA	Free	protease	inhibitor	per	
50mL	lysis	buffer),	and	lysed	by	microfluidizer	at	80psi.	The	lysate	was	spun	down	at	10,000g	
and	purified	by	batch	binding	using	TALON	beads	with	elution	buffer	(500	mM	NaCl,	20	mM	
TRIS	pH	8.0,	250	mM	imidazole).	The	His6-tag	was	cleaved	with	TEV	overnight	with	cleavage	
buffer	(300	mM	NaCl,	20	mM	TRIS	pH	8.0,	5	mM	imidazole,	1	mM	DTT,	0.5	mM	EDTA).	The	tag	
was	removed	via	Nickel	NTA	beads	and	the	eluate	was	purified	by	FPLC	using	ion	exchange	
(buffer	A:	50mM	NaCl,	20	mM	TRIS	pH	8.0,	buffer	B:	500mM	NaCl,	20	mM	TRIS	pH	8.0).	The	
protein	was	concentrated	to	5-20	mg/ml.	If	the	protein	was	used	for	crystallography	or	
hydrogen-deuterium	exchange,	it	was	subject	to	a	subsequent	size	exclusion	chromatography	
(buffer:	20	mM	HEPES	(pH	7.5),	150	mM	NaCl)	and	concentrated.	
X-ray	crystallization,	data	collection	and	refinement	
For	X-ray	crystallography,	1mM	MgCl2	and	40uM	GDP	(final	concentration)	was	added	to	
protein	additionally	purified	through	size	exclusion	chromatography.		Hanging	drop	
crystallization	conditions	were	set	up	by	mixing	1:1	protein	and	reservoir	solutions.	The	
reservoir	contained	5%	PEG400,	2M	(NH4)2SO4,	0.1M	HEPES	pH	7.5.		After	several	days	at	20°C,	
crystals	were	observed.	The	crystals	were	cryoprotected	in	crystallization	solution	
supplemented	with	28%	glycerol,	flash	frozen,	and	stored	in	liquid	nitrogen	prior	to	obtaining	
diffraction	data	at	8.2.1	beamline	at	the	Advanced	Light	Source	of	Lawrence	Berkeley	National	
Laboratories.	Data	was	indexed	with	IMOSFLM	and	scaled	and	solved	using	Aimless	and	Phaser-
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MR	(ccp4i)	and	then	subsequently	refined	with	Phenix	to	the	indicated	statistics	in	Table	
2.10.4.35	
Compound	stocks	
Few	unsubstituted-acrylamide	fragments	are	available	for	purchase.		Most	acrylamide	
fragments	were	synthesized	from	commercially	available	1°	and	2°	amines	using	1.1-fold	excess	
acryloyl	chloride	or	acrylic	acid	as	described.		After	purification,	the	compounds	were	made	into	
5mM	DMSO	stocks.	
Mass	Spectrometry	Screening	
50uL	of	4uM	K-Ras(G12C)-169	or	K-Ras(WT)	1-189	was	incubated	with	200uM	or	25uM	
compound	(4	or	2%	v/v	dimethylsulfoxide	respectively)	for	24	hours	at	room	temperature.	The	
reaction	was	quenched	with	2uL	10%	v/v	formic	acid	to	yield	0.4%	v/v	formic	acid	final.	Mass	
spectrometry	experiments	were	performed	using	the	Waters	Acquity	UPLC/ESI-TQD	with	a	
2.1 × 50 mm	Acquity	UPLC	BEH300	C4	column.	
Nucleotide	Exchange	Assay		
45uL	of	K-Ras(G12C)GDP	(111nM)	was	prepared	in	assay	buffer	(150mM	NaCl,	20mM	
HEPES,	pH	7.5,	104	uM	MgCl2,	0.01%	Triton	X-100)	was	added	to	a	96	well	Costar	plate.	
Exchange	was	catalyzed	by	the	addition	of	5uL	of	a	mixture	of	2uM	SOS	and	2uM	incoming	
nucleotide	(200nM	final;	ThermoFischerTM	BODIPY-FL	GDP	or	GTP)	and	fluorescence	intensity	
was	monitored	over	1	hour	at	Ex/Em:	485/520nm	using	a	BioTek	H4.	
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Thermal	Stability	Assays	
The	thermal	denaturation	of	K-Ras	was	monitored	using	a	fluorescence-based	
differential	scanning	fluorimetry	assay.	K-Ras	was	purified	with	or	without	compound	for	the	
use	of	the	experiment	as	previously	described.	8uM	protein	was	prepared	in	assay	buffer	
(150mM	NaCl,	20mM	Hepes,	pH	7.5,	1mM	MgCl2)	with	1/1000	Sypro	Orange.		The	plate	was	
heated	from	25-95°C	at	a	rate	of	0.5°C	/min.		The	fluorescence	intensity	was	monitored	at	
Ex/Em:	492/610nm.	
Hydrogen-deuterium	Exchange	Mass	Spectrometry	
HDX	reactions	were	conducted	with	40pmol	of	protein,	and	were	initiated	by	the	
addition	of	46	μL	of	D2O	Buffer	Solution	(10	mM	HEPES	pH	7.5,	50	mM	NaCl,	97%	D2O),	to	give	a	
final	concentration	of	87%	D2O.	Exchange	was	carried	out	for	0.3s,	3s,	30s,	300s	and	3000s,	and	
exchange	was	terminated	by	the	addition	of	a	quench	buffer	(final	concentration	0.6	M	
guanidine	HCl,	0.8%	formic	acid).	Samples	were	rapidly	frozen	in	liquid	nitrogen	and	stored	at	
−80°C	until	mass	analysis.	
Protein	samples	were	rapidly	thawed	and	injected	onto	a	UPLC	system	at	2°C.	The	
protein	was	run	over	two	immobilized	pepsin	columns	(Applied	Biosystems;	porosyme,	2-3131-
00)	at	10°C	and	2°C	at	200	μL/min	for	3	minutes,	and	peptides	were	collected	onto	a	VanGuard	
precolumn	trap	(Waters).	The	trap	was	subsequently	eluted	in	line	with	an	Acquity	1.7	μm	
particle,	100	×	1	mm2	C18	UPLC	column	(Waters),	using	a	gradient	of	5-36%	B	(buffer	A	0.1%	
formic	acid,	buffer	B	100%	acetonitrile)	over	16	minutes.	Mass	spectrometry	experiments	were	
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performed	on	an	Impact	II	TOF	(Bruker)	acquiring	over	a	mass	range	from	150	to	2200	m/z	using	
an	electrospray	ionization	source	operated	at	a	temperature	of	200°C	and	a	spray	voltage	of	4.5	
kV.	Peptides	were	identified	using	data-dependent	acquisition	methods	following	tandem	
MS/MS	experiments	(0.5	s	precursor	scan	from	150-2200	m/z;	twelve	0.25	s	fragment	scans	
from	150-2200	m/z).	MS/MS	datasets	were	analyzed	using	PEAKS7	(PEAKS),	and	a	false	
discovery	rate	was	set	at	1%	using	a	database	of	purified	proteins	and	known	contaminants.		
Deuterium	incorporation	calculations	were	carried	out	as	described	previously.36-38	HD-
Examiner	Software	(Sierra	Analytics)	was	used	to	automatically	calculate	the	level	of	deuterium	
incorporation	into	each	peptide.	All	peptides	were	manually	inspected	for	correct	charge	state	
and	presence	of	overlapping	peptides.	Deuteration	levels	were	calculated	using	the	centroid	of	
the	experimental	isotope	clusters.	Full	set	of	all	H/D	exchange	data	are	shown	in	Figure	2.10.1.	
Significant	changes	between	conditions	were	set	as	changes	greater	than	6%,	0.5	Da,	and	a	p-
value	<0.05	(student	t-test).		
	
	
Figure	2.10.1.	Relative	%deuterium	incorporation	in	peptides	of	K-Ras(G12C)	with	compounds	
10	and	11	over	time.	
S E Z RT Sequence 0.3s SD 3s SD 30s SD 300s SD 3000s SD 0.3s SD 3s SD 30s SD 300s SD 3000s SD 0.3s SD 3s SD 30s SD 300s SD 3000s SD
23 31 2 8.1 LIQNHFVDE 18.7 1.3 26.4 1.4 40.5 0.6 40.6 1.2 40.4 0.8 20.4 1.2 29.3 0.7 35.9 1.0 40.7 0.4 40.8 0.9 20.1 1.6 27.0 1.8 35.1 0.6 40.4 0.5 39.7 1.0 100
24 31 1 7.1 IQNHFVDE 19.3 0.8 27.0 0.9 36.0 0.6 35.4 1.0 34.7 1.0 20.9 1.1 29.6 0.8 33.8 0.9 34.8 0.7 34.6 0.4 20.7 0.6 27.7 1.8 33.9 1.0 34.7 0.4 34.0 0.5 90
24 37 2 9.8 IQNHFVDEYDPTIE 21.8 1.7 35.0 1.0 44.4 0.7 44.5 1.0 43.9 0.6 25.0 1.6 38.0 1.0 43.4 0.7 44.4 0.4 44.3 1.1 23.9 1.4 35.3 1.5 43.6 0.5 44.1 0.4 44.1 0.9 80
24 38 2 9.7 IQNHFVDEYDPTIED 20.7 1.7 32.8 1.8 42.2 0.8 42.2 1.2 41.5 0.5 23.5 1.8 35.6 1.2 40.7 0.6 41.7 0.6 41.8 1.5 22.2 1.7 33.2 1.5 40.5 0.3 41.2 0.5 41.5 1.2 70
24 39 2 9.7 IQNHFVDEYDPTIEDS 20.9 1.8 34.5 1.5 45.0 0.8 43.8 1.3 42.5 0.6 24.1 1.8 37.8 0.8 43.1 0.8 43.7 1.0 42.7 1.5 22.3 1.2 34.7 1.6 44.1 0.4 43.8 1.0 43.1 1.9 60
29 38 1 8.4 VDEYDPTIED 23.9 2.1 40.0 0.5 47.4 1.5 46.8 1.0 44.8 1.3 26.5 1.2 42.1 0.6 44.9 1.3 44.7 1.7 42.5 1.5 24.5 3.1 39.4 2.7 44.9 1.2 43.6 1.2 40.3 0.0 50
32 39 1 7.1 YDPTIEDS 29.8 2.2 53.9 1.4 68.8 1.4 68.1 1.1 67.4 1.9 35.3 2.1 59.8 0.3 66.3 0.9 67.4 0.4 66.5 1.3 31.3 2.1 54.6 3.8 66.8 1.0 66.8 0.8 64.8 0.7 40
34 39 1 5.2 PTIEDS 32.8 0.6 55.4 2.1 70.6 1.2 71.1 0.7 68.4 2.4 39.1 2.0 62.3 0.8 68.6 1.3 68.9 0.7 68.0 0.6 35.4 2.2 57.4 4.3 68.9 1.2 68.9 1.9 65.8 0.8 30
38 52 2 8.4 DSYRKQVVIDGETSL 26.1 1.4 35.1 1.6 52.6 0.8 64.8 0.9 72.2 1.0 25.9 1.1 36.2 0.4 42.4 0.4 67.7 0.4 73.2 0.1 26.7 0.3 35.7 1.2 41.8 0.3 61.4 0.3 72.6 0.6 20
39 52 3 8.0 SYRKQVVIDGETSL 25.4 1.1 33.4 1.3 49.6 0.5 62.4 1.2 70.4 0.7 25.7 1.0 34.1 0.4 39.3 0.8 65.3 1.0 71.9 0.3 27.8 1.7 34.0 1.2 38.4 0.5 58.9 0.8 71.2 1.0 10
40 52 2 7.9 YRKQVVIDGETSL 25.8 1.0 32.6 1.1 47.3 0.6 61.0 0.9 69.5 0.6 26.1 1.0 33.3 0.3 36.9 0.6 63.9 1.0 71.2 0.5 27.9 1.2 33.1 1.0 36.0 0.5 57.2 0.7 70.5 0.9 0
53 63 1 10.1 LDILDTAGQEE 24.8 1.1 31.5 1.9 46.3 1.1 55.7 1.6 61.7 0.8 24.6 1.5 33.0 1.3 38.9 0.4 53.8 1.4 62.9 1.3 24.4 0.5 32.3 1.3 38.7 0.3 47.6 0.8 60.8 0.8
54 80 3 13.3 DILDTAGQEEYSAMRDQYMRTGEGFLL 33.0 0.8 44.2 0.8 55.0 0.8 58.3 1.3 60.6 0.5 32.1 1.3 45.0 0.9 53.3 1.0 58.3 1.0 62.0 0.0 33.2 1.6 42.7 1.2 53.3 0.6 56.1 0.9 61.6 1.6
57 67 1 8.0 DTAGQEEYSAM 57.0 0.6 60.8 0.9 66.1 0.4 65.6 1.4 64.8 1.0 56.3 1.7 61.3 1.8 65.5 1.1 66.2 0.3 65.8 0.6 56.8 0.8 61.9 1.5 65.7 1.4 66.0 0.4 65.7 0.8
68 79 3 9.8 RDQYMRTGEGFL 11.5 1.1 20.9 0.9 32.8 0.6 33.3 0.6 35.9 0.3 10.3 0.6 20.6 0.4 32.5 0.4 34.3 0.3 38.3 0.4 10.6 0.6 18.8 0.9 31.7 0.4 33.5 0.2 36.0 0.5
72 79 2 9.7 MRTGEGFL 11.2 0.7 15.0 0.6 18.7 0.4 19.5 0.4 23.4 0.3 9.9 0.5 14.7 0.6 19.0 0.3 20.6 0.3 26.9 0.3 10.3 0.6 14.2 0.3 18.7 0.2 19.6 0.1 23.6 0.3
82 113 5 9.6 FAINNTKSFEDIHHYREQIKRVKDSEDVPMVL 7.1 0.6 8.5 0.5 9.9 0.4 15.9 0.7 26.2 0.6 7.8 0.4 8.4 0.6 10.7 0.4 18.7 0.5 31.5 0.5 7.7 0.2 8.5 0.2 9.8 0.3 15.6 0.2 25.7 1.3
83 90 1 6.3 AINNTKSF 24.3 0.6 27.1 0.5 30.8 0.3 51.7 1.0 66.9 1.1 25.4 0.9 27.7 0.1 31.0 0.2 57.3 1.1 69.1 0.4 26.1 0.2 27.6 0.7 31.2 0.5 54.8 1.0 68.6 1.1
83 91 2 6.3 AINNTKSFE 20.9 0.4 23.0 0.6 26.0 0.5 44.2 0.8 60.1 1.1 21.5 0.6 23.4 0.5 26.6 0.4 51.4 1.1 66.9 0.1 21.8 0.4 23.6 0.7 26.5 0.3 47.6 0.7 64.2 1.2
83 113 5 9.1 AINNTKSFEDIHHYREQIKRVKDSEDVPMVL 7.5 0.7 9.0 0.2 10.3 0.4 15.6 0.8 25.7 0.8 8.2 0.4 8.8 0.6 10.9 0.6 18.1 0.5 29.7 0.4 8.1 0.3 8.9 0.4 10.2 0.3 15.3 0.3 24.6 1.2
90 113 5 9.2 FEDIHHYREQIKRVKDSEDVPMVL 9.0 0.8 10.8 0.6 12.5 0.5 18.3 0.8 29.7 1.1 9.9 0.4 10.6 0.7 13.3 0.7 20.5 0.6 33.6 0.4 9.7 0.4 10.8 0.5 12.4 0.4 17.5 0.3 27.4 0.7
91 113 4 8.6 EDIHHYREQIKRVKDSEDVPMVL 9.6 0.8 11.3 0.6 13.2 0.4 19.2 0.8 30.3 0.9 10.3 0.4 11.2 0.7 14.1 0.7 21.2 0.6 34.0 0.3 10.1 0.5 11.6 0.6 13.0 0.5 18.0 0.4 28.0 0.7
92 113 3 8.5 DIHHYREQIKRVKDSEDVPMVL 10.0 0.7 11.8 0.6 13.7 0.4 19.9 0.8 31.0 0.9 10.7 0.5 11.6 0.7 14.5 0.7 21.6 0.5 34.2 0.2 10.5 0.4 12.0 0.6 13.5 0.4 18.4 0.4 28.4 0.8
114 124 3 4.6 VGNKSDLPSRT 22.9 0.6 27.9 0.5 34.2 0.0 43.0 0.3 56.4 1.7 23.6 0.9 28.9 0.1 34.3 0.5 47.1 0.5 62.0 1.0 25.0 0.2 29.9 1.4 34.1 0.4 47.0 1.2 60.8 1.6
114 126 3 5.3 VGNKSDLPSRTVD 20.6 0.8 26.9 0.9 34.9 0.2 47.6 0.6 58.0 1.4 21.1 0.8 28.1 0.3 34.8 0.5 50.5 0.9 61.6 0.3 23.4 0.3 29.2 1.4 35.2 0.5 50.2 1.1 60.9 1.1
114 132 3 5.0 VGNKSDLPSRTVDTKQAQD 19.1 0.9 26.1 0.6 34.1 0.4 44.4 0.4 55.9 1.6 20.2 0.8 27.0 0.6 34.0 0.6 48.9 0.8 62.2 0.4 22.0 0.1 27.9 1.1 34.4 0.7 46.5 0.8 59.5 1.7
114 133 3 6.7 VGNKSDLPSRTVDTKQAQDL 16.2 0.7 22.4 0.5 29.9 0.4 39.0 0.6 50.1 0.7 17.1 0.9 23.0 0.4 29.8 0.5 44.0 1.1 58.1 0.0 18.5 0.5 23.8 1.0 30.0 0.9 40.8 0.8 53.6 1.3
114 144 5 11.1 VGNKSDLPSRTVDTKQAQDLARSYGIPFIET 7.4 0.5 11.1 0.4 16.9 0.3 28.6 0.7 41.0 0.1 8.4 0.5 11.4 0.4 17.2 0.3 34.9 0.8 52.9 0.2 9.0 0.2 11.3 0.3 17.6 0.1 30.3 0.1 44.0 1.3
133 144 2 11.6 LARSYGIPFIET 1.7 0.1 2.4 0.1 7.5 0.1 24.5 0.2 39.3 0.1 2.0 0.3 2.5 0.1 8.0 0.2 31.4 0.6 51.6 0.0 1.9 0.2 2.7 0.1 8.5 0.1 26.0 0.2 41.2 0.6
134 144 2 11.2 ARSYGIPFIET 2.0 0.1 2.6 0.1 7.9 0.2 25.6 0.2 41.4 0.2 2.3 0.4 2.9 0.2 8.5 0.1 32.6 0.8 52.2 0.0 2.2 0.1 3.1 0.1 9.0 0.1 27.1 0.1 43.1 0.6
134 156 3 10.5 ARSYGIPFIETSAKTRQGVDDAF 3.5 0.2 4.4 0.2 11.0 0.1 26.3 0.7 38.1 0.1 4.0 0.3 4.6 0.2 10.6 0.1 30.8 0.1 43.5 0.2 3.8 0.2 4.7 0.1 10.7 0.1 27.6 0.3 39.3 0.9
137 144 1 12.5 YGIPFIET 1.7 0.2 2.6 0.2 9.6 0.1 27.9 0.0 38.4 0.2 2.5 0.9 2.8 0.2 10.3 0.3 32.0 0.7 47.7 0.1 3.0 0.7 3.3 0.1 10.9 0.1 28.3 0.0 38.3 0.3
145 156 2 6.8 SAKTRQGVDDAF 7.2 0.2 8.5 0.1 18.2 0.4 35.8 1.0 45.4 0.8 7.5 0.3 9.0 0.2 16.6 0.4 38.6 1.1 49.3 0.3 7.5 0.1 9.1 0.5 16.6 0.5 35.3 1.2 45.6 1.0
157 169 3 4.5 YTLVREIRKHKEK 1.5 0.1 2.6 0.1 7.8 0.1 12.4 0.1 13.8 1.4 1.7 0.2 2.8 0.2 7.7 0.3 12.2 0.4 15.1 0.7 1.8 0.1 3.0 0.3 7.7 0.3 11.7 0.5 14.0 1.2
160 169 3 2.7 VREIRKHKEK 2.9 0.2 4.9 0.2 12.0 0.2 18.2 0.4 21.3 0.7 3.0 0.4 5.4 0.6 12.1 1.3 17.9 0.8 20.1 2.7 3.4 0.6 5.5 1.2 12.7 0.6 17.1 1.6 19.8 2.5
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Figure	 2.10.2.	 Relative	 %deuterium	 incorporation	 over	 time	 in	 a.	 	 peptides	 34-39	 (Switch-I	
region)	b.	 peptides	 38-52	 c.	 	 peptides	 53-63	 (Switch-II	 region)	 and	d.	peptides	133-144.	HDX	
curves	are	the	average	of	three	independent	experiments	(error	bars	represent	SD).	
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Table	2.10.1.	Crystal	structures	used	for	docking.	
Ligand-bound	K-Ras	monomers	used	for	docking	studies	
4M21	chain	B	 4M1S	chain	B		 4M22	chain	B	 56A	chain	B*	
4LYJ	 4LUC	chain	A		 4M22	chain	C	 56A	chain	C*	
4LYH	chain	B		 4LUC	chain	B	 4M1T	chain	B		 56A	chain	D*	
4LYH	chain	C		 4LV6	chain	A		 59	chain	B*	 56A	chain	E*	
4LYF	chain	B		 4LV6	chain	B		 59	chain	C*	 55_P1	chain	A*	
4M1Y	chain	B	 4M1O	chain	B		 56A	chain	A*	 55_P1	chain	B*	
*Crystal	structures	are	not	deposited	in	the	Protein	Data	Bank.	
	
	
	
	
Table	 2.10.2.	 Percent	 modification	 of	 Cys-light	 K-Ras(G12C)	 1-169	 and	 K-Ras(WT)	 1-189	 by	
compounds	in	DOCKovalent	Library	
	
Compound	
Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	
S1-1	 287.40	 0	 0	
	
S1-2	 295.38	 0	 0	
	
S1-3	 255.31	 0	 0	
	
S1-4	 281.35	 0	 0	
	
S1-5	 293.36	 0	 61.7	
	
S1-6	 258.36	 0	 0	
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Compound	
Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	
S1-7	 255.31	 0	 24.2	
	
S1-8	 243.26	 0	 0	
	
S1-9	 290.33	 0	 0	
	
S1-10	 271.31	 0	 0	
	
S1-11	 301.38	 0	 0	
	
	
S1-12	
	
227.26	 0	 0	
	
S1-13	
	 298.42	 0	 0	
	
2	 289.40	 20	 0	
	
S1-14	 290.36	 0	 0	
	
1	 294.35	 41	 43.5	
	
S1-15	
	 262.73	 0	 0	
	
S1-16	
	 273.33	 0	 23.6	
	
S1-17	 239.27	 0	 0	
NN N
O
N N
O HN
O
N
O
N O
F
MeO N
N N
O
H
N
O
N
N
O
NHN HN
O
N
N O
N
S
NH
N
O
MeO
OMe
N
HN
O
H
N
O
N
O
H
NCl
N
O
H
N
O
N
N
O
O H
N
O
 40	
Compound	
Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	 S1-18	 281.31	 0	 0	
	
S1-19	 272.27	 0	 0	
	
S1-20	 296.39	 0	 0	
	
S1-21	 273.29	 0	 20.2	
	
S1-22	 296.37	 0	 0	
	
S1-23	 296.36	 0	 21.4	
	 S1-24	 297.39	 0	 0	
	
S1-25	 265.74	 0	 0	
	
S1-26	 246.31	 0	 0	
	
S1-27	 272.34	 0		 20	
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Table	 2.10.3.	 Percent	 modification	 of	 Cys-light	 K-Ras(G12C)	 1-169	 and	 K-Ras(WT)	 1-189	 by	
compounds	in	Acrylamide	Library	
Compound	Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	
DKM-2-31	 161.20	 0	 0	
	
DKM-2-32	 203.28	 0	 0	
	
DKM-2-34	 179.19	 0	 0	
	
DKM-2-37	 237.30	 0	 0	
	
DKM-2-39	 212.25	 0	 18.2	
	
DKM-2-40	 183.15	 40.4	 100	
	
DKM-2-43	 240.10	 0	 0	
	
DKM-2-47	 189.25	 0	 0	
	
DKM-2-49	 141.17	 0	 22.4	
	
DKM-2-50	 189.25	 0	 0	
	
DKM-2-58	 221.25	 0	 0	
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Compound	Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	
DKM-2-59	 237.30	 0	 0	
	
DKM-2-60	 195.65	 0	 0	
	
DKM-2-84	 187.24	 0	 30.0	
	
DKM-2-85	 219.24	 56.5	 100	
	
DKM-2-86	 191.18	 0	 38.0	
	
DKM-2-87	 205.21	 0	 40.0	
	
DKM-2-95	 175.23	 0	 0	
	
DKM-2-97	 215.29	 0	 0	
	
DKM-2-98	 248.28	 0	 0	
	 DKM-2-99	 111.14	 0	 0	
	
DKM-2-100	 184.24	 0	 0	
	
DKM-2-101	 173.21	 41.7	 100	
	 DKM-2-102	 127.18	 0	 0	
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Compound	Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	 DKM-2-103	 143.18	 0	 0	
	
DKM-2-104	 192.17	 100	 100	
	
DKM-2-107	 181.62	 0	 31.0	
	 DKM-2-108	 139.19	 0	 0	
	
DKM-2-109	 169.22	 0	 0	
	
DKM-2-110	 221.25	 0	 0	
	
DKM-2-111	 240.30	 0	 0	
	
DKM-2-113	 191.23	 0	 0	
	
DKM-2-114	 235.37	 0	 0	
	
DKM-2-116	 229.20	 0	 0	
	
DKM-2-117	 251.28	 100	 100	
	
DKM-2-119	 239.27	 38.8	 43	
	
DKM-2-120	 211.26	 0	 0	
	
DKM3-3	 292.16	 16.3	 0	
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Compound	Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	
DKM-3-4	 237.30	 0	 0	
	
DKM-3-5	 216.28	 0	 15.7	
	
DKM-3-7	 189.21	 53	 100	
	
DKM-3-8	 153.22	 0	 0	
	
DKM-3-9	 187.24	 0	 0	
	
DKM-3-10	 193.27	 0	 62.5	
	
DKM-3-12	 144.21	 0	 0	
	
DKM-3-15	 155.19	 0	 0	
	
DKM-3-16	 251.32	 0	 0	
	 DKM3-30	 273.71	 0	 0	
	
DKM3-31	 165.16	 0	 41.6	
	 DKM-3-32	 127.18	 0	 0	
	
DKM-3-36	 246.30	 0	 19.3	
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Compound	Structure	 Name	 Mass	
	
%	Labeling	of	
K-Ras(G12C)	
	
%	Labeling	of	
K-Ras(WT)	1-
189	
	
DKM-3-41	 313.39	 0	 0	
	 DKM-3-42	 207.31	 0	 0	
	
DKM-3-43	 205.21	 0	 0	
	
DKM3-70	 223.27	 52	 100	
	
TRH-1-12	 211.34	 0	 0	
	
TRH-1-13	 221.25	 0	 0	
	
TRH-1-19	 147.17	 0	 28.2	
	
TRH-1-20	 175.23	 0	 0	
	
TRH-1-27	 167.25	 0	 0	
	
TRH-1-30	 157.23	 0	 24.5	
	
TRH-1-32	 177.20	 0	 20.9	
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Table	2.10.4.		Data	collection	and	refinement	statistics	for	K-Ras(G12C)-10	(PDB:	6ARK).	
	 K-Ras(G12C)-10	
Data	Collection	 	
Space	group	 H	3	2	
Cell	Dimension	
a,	b,	c	(Å)	
(°)	
	
94.2799,	94.2799,	119.55	
90,	90,	120	
Resolution	range	(Å)	 30.43		-	1.75	(1.78		-	1.75)	
Rmerge	 0.072	(0.996)	
Rpim	 0.033	(0.451)	
Mean	I/σI	 13.60	
CC1/2	 0.999	(0.702)	
Completeness	(%)	 100.00	(100.00)	
Multiplicity	 2.0	(2.0)	
Refinement	 	
Resolution	(Å)	 29.88		-	1.75	
Reflections	used	in	
refinement	 39968	
Rwork/Rfree	 0.1937/0.2314	
Number	of	atoms	 1444	
Protein	 1323	
Ligands/ions	 65	
Water	 56	
B-factors	 52.59	
Protein	 53.04	
Ligands/ions	 52.11	
Water	 42.50	
R.m.s.	deviations	 	
Bonds	(Å)	 0.006	
Angles	(°)	 0.98	
*Statistics	for	the	highest-resolution	shell	are	shown	in	parentheses.	
	
	
	
Synthetic	Methods	
All	commercial	reagents	were	purchased	and	used	without	further	purification.		All	reactions	
were	done	under	argon	in	sealed	vials	with	stirring.	Silica	gel	chromatography	was	performed	
using	a	Combiflash	Rf	(Teledyne	Isco)	with	pre-packed	4-24g	silica	columns	and	cartridges.		All	
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reverse-phase	high	performance	liquid	chromatography	(RP-HPLC)	was	performed	using	a	
Waters	2545	solvent	delivery	system	equipped	with	an	XBridge	prep	C18	column.	Separation	
was	achieved	using	a	gradient	between	5-95%	acetonitrile	(ACN)	in	water	with	0.1%	formic	acid	
by	monitoring	UV	absorption	(λ=254	nm).	For	most	compounds,	high-resolution	mass	
spectrometry	(HRMS)	was	performed	using	a	high-resolution	UPLC/TOF	system	(Synapt	G2-S,	
Waters)	equipped	with	ESI	source.	Compounds	were	analyzed	in	positive	ionization	mode.	
Separation	was	done	on	Acquity	BEH	C18	column	using	water-methanol-formic	acid	gradient	
for	elution.	Elemental	composition	was	determined	using	Elemental	Composition	module	of	
MassLynx	v.4.1	software.	Liquid	chromatography	traces	and	MS	(for	S1-14	and	S1-20)	were	
collected	with	a	Waters	Acquity	UPLC	Class	I/XEVO	G2-XS	QToF	with	a	2.1	x	50	mm	Acquity	
UPLC	BEH	C18	column.	1H	NMR	were	recorded	on	a	Varian	Innova	400	MHz	or	a	Bruker	DRX	
500	MHz	spectrometer.	1H	chemical	shifts	are	reported	in	δ	(ppm)	as	s	(singlet),	d	(doublet),	dd	
(doublet	of	doublets),	t	(triplet),	q	(quartet),	or	m	(multiplet)	and	are	referenced	to	the	residual	
solvent	peak.		Coupling	constants	(J)	are	reported	as	Hertz.	13C	NMR	were	recorded	on	a	Bruker	
DRX	500	MHz	spectrometer	and	the	13C	chemical	shifts	are	reported	in	δ	(ppm)	and	are	
referenced	to	the	residual	solvent	peak.		
	
	
S1-1	1-(4-(2-(2,5-dimethylphenoxy)ethyl)piperidin-1-yl)prop-2-en-1-one:	
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4-(2-(2,5-Dimethylphenoxy)ethyl)piperidine	hydrochloride	(50mg,	1	eq,	0.19	mmol)	was	
dissolved	in	2mL	acetonitrile.		TEA	was	added	(150uL,	6	eq,	1.11mmol)	at	ambient	temperature.		
The	reaction	was	cooled	to	0°C.	Acryloyl	chloride	(16uL,	1.1	eq,	0.20mmol)	was	added	and	
reaction	was	stirred	for	30	minutes.	The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	
dried	over	Na2SO4.		The	compound	was	purified	by	flash	chromatography	on	silica	gel	(0-15%	
dichloromethane:	methanol	gradient)	and	subsequently	by	RP-HPLC	(45-95%	gradient)	to	get	
the	desired	product	the	desired	product	(11.8mg,	22%yield)	as	a	yellow	oil.	HRMS	C18H26NO2	
[M+H]+	expected	mass:	288.1964;	observed:	288.1972.	1H	NMR	(400	MHz,	CDCl3)	δ	7.01	(d,	
J=7.54,	1H),	6.67	(d,	J=7.52,	1H),	6.62	(s,	1H),	6.59	(dd,	J=16.96,	10.60,	1H),	6.26	(dd,	J=16.86,	
1.97,	1H)	5.66	(dd,	J=10.59,	1.97,	1H),	4.66	(d,	J=12.70,	1H),	4.00	(t,	J=6.21,	2H),	3.98	(m,	1H)	
3.06	(t,	J=12.71,	1H),	2.65(t,	J=12.63,	1H)	2.31	(s,	3H),	2.17	(s,	3H),	1.84	(m,	3H),	1.77	(q,	J=6.23,	
2H),	1.23	(m,	2H).		
	
	
S1-2	(R)-1-(3-((naphthalen-2-yloxy)methyl)piperidin-1-yl)prop-2-en-1-one:	
3-[(2-Naphthyloxy)methyl]piperidine	(50mg,	1	eq,	0.18	mmol)	was	dissolved	in	2mL	acetonitrile.		
TEA	was	added	(250uL,	5eq,	0.9mmol)	at	ambient	temperature.		The	reaction	was	cooled	to	
0°C.	Acryloyl	chloride	(30uL,	2	eq,	0.4mmol)	was	added	and	reaction	was	stirred	for	30	minutes.		
The	reaction	was	quenched	with	5mL	saturated	NaHCO3.		The	reaction	was	extracted	with	ethyl	
acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	chromatography	on	
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silica	gel	(5-100%	hexanes:	ethyl	acetate	gradient)	to	get	the	desired	product	(25mg,	47%yield)	
as	a	yellow	oil.	HRMS	C19H22NO2	[M+H]+	expected	mass:	296.1651;	observed:	296.1664.	1H	NMR	
(400	MHz,	CDCl3)	δ	7.74	(m,	3H),	7.44	(m,	1H),	7.34	(m,	1H),	7.15	(d,	J=8.92,	1H),	7.11	(s,	1H),	
6.62	(m,	1H),	6.27	(t,	J=16.37,	1H),	5.66	(dd,	J=16.73,	10.79,	1H),	4.48	(dd,	J=170.32,	13.47,	1H),	
3.98	(m,	3H),	2.97	(m,	1H),	3.10	(m,	1H),	2.13	(m,	1H),	1.98	(m,	1H),	1.79	(m,	2H),	1.54	(m,	1H).		
	
S1-3	1-(4-(1H-benzo[d]imidazol-1-yl)piperidin-1-yl)prop-2-en-1-one:	
1-(piperidin-4-yl)-1H-1,3-benzodiazole	hydrochloride	(27mg,	1	eq,	0.13	mmol)	was	dissolved	in	
2mL	acetonitrile.		TEA	was	added	(35uL,	1.9	eq,	0.247mmol)	at	ambient	temperature.		The	
reaction	was	cooled	to	0°C.		Acryloyl	chloride	(8uL,	0.8	eq,	0.1mmol)	was	added.		The	reaction	
was	quenched	with	5mL	saturated	NaHCO3.			The	reaction	was	extracted	with	ethyl	acetate	
(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	chromatography	on	silica	gel	
(0-15%	dichloromethane:	methanol)	to	get	the	desired	product	(15.7mg,	50%yield)	as	a	white	
solid.	HRMS	C15H18N3O	[M+H]+	expected	mass:	256.145;	observed:	256.145.	1H	NMR	(400	MHz,	
CD3OD)	δ	8.28	(s,	1H),	7.71	(m,	2H),	7.30	(m,	2H),	6.84	(dd,	J=16.56,10.64,	1H),	6.24	(dd,	
J=16.79,	2.02,	1H),	5.78	(dd,	J=10.59,	2.02,	1H),	4.73	(m,	2H),	4.34	(d,	J=13.41,	1H),	3.39	(t,	
J=13.41,	1H),	2.97	(t,	J=13.41,	1H),	2.25	(d,	J=12.49),	2.09	(m,	2H).	
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S1-4	N-((2-(3,4-dihydroisoquinolin-2(1H)-yl)pyridin-3-yl)methyl)acrylamide:		
1-benzyl-4,5,6,7-tetrahydro-1H-indazol-4-amine	(75mg,	1	eq,	0.33mmol)	was	dissolved	in	2mL	
acetonitrile.		TEA	was	added	(90uL,	2	eq,	0.66mmol)	at	ambient	temperature.		The	reaction	was	
cooled	to	0°C.		Acryloyl	chloride	(30uL,	1.1	eq,	0.36mmol)	was	added.		The	reaction	was	
quenched	with	5mL	saturated	NaHCO3.	The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	
3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	chromatography	on	silica	gel	(5-
100%	hexanes:	ethyl	acetate)	to	get	the	desired	product	(7mg,	8%yield)	as	a	yellow	oil.	HRMS	
C17H20N3O	[M+H]+	expected	mass:	282.1606;	observed:	282.1608.	1H	NMR	(400	MHz,	CD3OD)	δ	
7.40	(s,	1H),	7.29	(m,	3H),	7.12	(d,	J=7.25,	2H),	5.65	(dd,	J=6.88,	5.00,	1H),	6.25	(m,	2H),	5.26	(s,	
2H),	5.04	(t,	J=4.91,	1H),	2.55	(m,	2H),	1.93	(m,	2H),	1.82	(m,	1H),	1.70	(m,	1H).	
	 	
S1-5	N-((2-(3,4-dihydroisoquinolin-2(1H)-yl)pyridin-3-yl)methyl)acrylamide:	
	(2-(3,4-Dihydroisoquinolin-2(1H)-yl)pyridin-3-yl)methanamine	(50mg,	1	eq,	0.208mmol)	was	
dissolved	in	2mL	acetonitrile.	TEA	was	added	(58uL,	2	eq,	0.416mmol)	at	ambient	temperature.		
The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(19uL,	1.1	eq,	0.229mmol)	was	added.		The	
reaction	was	quenched	with	5mL	saturated	NaHCO3.			The	reaction	was	extracted	with	ethyl	
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acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	chromatography	on	
silica	gel	(5-100%	hexanes:	ethyl	acetate)	to	get	the	desired	product	(8.2mg,	13%yield)	as	a	
white	oily	solid.	HRMS	C18H20N3O	[M+H]+	expected	mass:	294.1606;	observed:	294.1609.	1H	
NMR	(400	MHz,	CDCl3)	δ	8.29	(dd,	J=4.87,	1.72,	1H),	7.59	(dd,	J=7.49,	1.64,	1H),	7.19	(m,	3H),	
7.15	(m,	1H),	6.99	(dd,	J=4.92,	7.47,	1H),	6.42	(s,	1H),	6.26	(dd,	J=16.98,	1.24,	1H),	6.05	(dd,	
J=17.00,	10.31,	1H),	5.63	(dd,	J=10.31,	1.21,	1H),	4.64	(d,	J=5.91,	2H),	4.39	(s,	2H),	3.40	(t,	
J=5.80,	2H),	3.07	(t,	J=5.72,	2H).	13C	NMR	(400	MHz,	CDCl3)	δ	165.78,	161.19,	147.05,	137.84,	
134.91,	134.22,	130.71,	129.04,	127.01,	126.87,	126.55,	126.11,	125.41,	118.91,	77.39,	52.24,	
49.62,	40.05,	29.84.	
	
	
S1-6	N-(2-(azepan-1-yl)benzyl)acrylamide:	
	[2-(1-Azepanyl)phenyl]methanamine	(61mg,	1	eq,	0.3mmol)	was	dissolved	in	2mL	acetonitrile.		
TEA	(70uL,	2eq,	0.5mmol)	was	added	at	ambient	temperature.		The	reaction	was	cooled	to	0°C.		
Acryloyl	chloride	(22uL,	1.1	eq,	0.27mmol)	was	added.		The	reaction	was	quenched	with	5mL	
saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.			The	reaction	was	
extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate)	to	get	the	desired	product	
(32.8mg,	42%yield)	a	white	oily	solid.	HRMS	C16H23N2O	[M+H]+	expected	mass:	259.181;	
observed:	259.1819.	1H	NMR	(400	MHz,	CDCl3)	δ	7.24	(m,	2H),	7.16	(d,	J=8.13,	1H),	7.03	(t,	
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J=7.04,	1H),	6.97	(s,	1H),	6.29	(dd,	J=16.96,	1.25,	1H),	6.10	(dd,	J=16.92,	10.25,	1H),	5.64	(dd,	
J=10.23,	1.24,	1H),	4.61	(d,	J=5.51,	2H),	3.10	(t,	J=5.31,	4H),	1.73	(m,	8H).	
	
	
S1-7	N-methyl-N-((1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl)acrylamide:	
N-methyl-1-(1-methyl-3-phenyl-1H-pyrazol-5-yl)methanamine	(25mg,	1	eq,	0.124mmol)	was	
dissolved	in	2mL	acetonitrile.		TEA	(35uL,	2	eq,	0.25mmol)	was	added	at	ambient	temperature.	
The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(11uL,	1.1	eq,	0.136mmol)	was	added.		The	
reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	
temperature.		The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.	The	
compound	was	purified	by	flash	chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate)	
to	get	the	desired	product	(17.6mg,	56%	yield)	as	a	white	oily	solid.	HRMS	C15H18N3O	[M+H]+	
expected	mass:	256.145;	observed:	256.1458.	1H	NMR	(400	MHz,	CDCl3)	δ	7.76	(d,	J=7.62,	2H),	
7.38	(t,	J=7.44,	2H),	7.30	(d,	J=7.44,	1H),	6.61	(dd,	J=10.40,	16.78,	1H),	6.50	(s,	1H)	6.40	(dd,	
J=16.78,	1.95,	1H),	5.77(d,	J=10.69,	1H),	4.75	(s,	2H),	3.89	(s,	3H),	3.05	(s,	3H).	
	
	
S1-8	N-((5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)methyl)acrylamide:	
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5-(Aminomethyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one	dihydrochloride	(25mg,	1	eq,	
0.13mmol)	was	dissolved	in	2mL	acetonitrile.		TEA	(37uL,	2eq,	0.26mmol)	was	added	at	ambient	
temperature.		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(12uL,	1.1	eq,	0.15mmol)	was	
added.		The	reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	
at	ambient	temperature.			The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	
Na2SO4.	The	compound	was	purified	by	flash	chromatography	on	silica	gel	(5-100%	hexanes:	
ethyl	acetate)	to	get	the	desired	product	(3mg,	9%yield)	as	a	yellow	oil.	HRMS	C13H14N3O2	
[M+H]+	expected	mass:	244.1086;	observed:	244.1089.	1H	NMR	(400	MHz,	MeOD)	δ	7.66	(t,	
J=7.70,	2H),	7.44	(t,	J=7.70,	2H),	7.29	(t,	J=7.69,	1H),	6.29	(m,	2H),	5.69	(dd,	J=	8.35,	3.65,	1H),	
4.37	(s,	2H).	
	
	
	
S1-9	1-(4-(3-(3-fluorophenyl)propanoyl)piperazin-1-yl)prop-2-en-1-one:	
3-(3-Fluorophenyl)-1-(piperazin-1-yl)propan-1-one	hydrochloride	(25mg,	1	eq,	0.11mmol)	was	
dissolved	in	2mL	acetonitrile.		TEA	(30uL,	2eq,	0.21mmol)	was	added	at	ambient	temperature.	
The	reaction	was	cooled	to	0°C.	Acryloyl	chloride	(10uL,	1.1	eq,	0.11mmol)	was	added.	The	
reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	
temperature.	The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.	The	
compound	was	purified	by	flash	chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate)	
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to	get	the	desired	product	(12.8mg,	40%yield)	as	a	clear	oil.	HRMS	C16H20FN2O2	[M+H]+	
expected	mass:	291.1509;	observed:	291.1509.	1H	NMR	(400	MHz,	CDCl3)	δ	7.25	(m,	1H),	7.00	
(d,	J	=7.61,	1H),	6.90	(m,	2H),	6.53	(m,	1H),	6.32	(dd,	J=16.97,	1.70,	1H),	5.74	(dd,	J=10.56,	1.57,	
1H),	3.55	(m,	8H),	2.99	(t,	J=	7.40,	2H),	2.64	(t,	J=7.40,	2H).	13C	NMR	(500	MHz,	CDCl3)	δ	170.78,	
165.74	+	164.02	(d,	J=214.72),	162.06,	143.67,	130.19	+	130.12	(d,	J=8.32),	129.00,	127.06,	
124.28,	115.56	+	115.39	(d,	J=21.09),	113.45	+	113.28	(d,	J=21.09),	45.60,	45.25,	41.79,	41.44,	
34.68,	31.13.	
	
S1-10	N-((1-(3-methoxyphenyl)-1H-pyrazol-4-yl)methyl)-N-methylacrylamide:	
1-[1-(3-methoxyphenyl)-1H-pyrazol-4-yl]-N-methylmethanamine	(57.6mg,	1	eq,	0.229mmol)	
was	dissolved	in	2mL	acetonitrile.		TEA	(64uL,	2eq,	0.458mmol)	was	added	at	ambient	
temperature.		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(20uL,	1.1	eq,	0.252mmol)	was	
added.		The	reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	
at	ambient	temperature.			The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	
Na2SO4.		The	compound	was	purified	by	flash	chromatography	on	silica	gel	(5-100%	hexanes:	
ethyl	acetate)	to	get	the	desired	product	(29.6mg,	48%yield)	as	a	clear	oil.	HRMS	C15H18N3O2	
[M+H]+	expected	mass:	272.1399;	observed:	272.1404.	1H	NMR	(400	MHz,	CDCl3)	δ	7.32	(t,	
J=8.06,	1H),	7.20	(d,	J=8.06,	1H),	6.82	(d,	J=8.06,	1H),	6.58	(dd,	J=16.83,	10.27,	1H),	6.37	(dd,	
J=16.74,	1.78,	1H),	5.73	(dd,	J=10.40,	1.68,	1H),	4.54	(s,	2H),	3.86	(s,	3H),	3.07	(s,	3H).	
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S1-11	2-(4-acryloylpiperazin-1-yl)-N-(2,4-dimethylphenyl)acetamide:	
N-(2,4-dimethylphenyl)-2-piperazin-1-yl-acetamide	(25mg,	1	eq,	0.10mmol)	was	dissolved	in	
2mL	acetonitrile.		TEA	(28uL,	2eq,	0.20mmol)	was	added	at	ambient	temperature.		The	reaction	
was	cooled	to	0°C.		Acryloyl	chloride	(9uL,	1.1	eq,	0.11mmol)	was	added.		The	reaction	was	
quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.			
The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	
was	purified	by	flash	chromatography	on	silica	gel	(0-15%	dichloromethane:	methanol)	to	get	
the	desired	product	(9mg,	30%	yield)	a	white	solid.	HRMS	C17H24N3O2	[M+H]+	expected	mass:	
302.1869;	observed:	302.1874.	1H	NMR	(400	MHz,	CDCl3)	δ	9.06	(s,	1H)	7.94	(s,	1H),	7.06	(d,	
J=7.59,	1H),	6.88	(d,	J=7.70,	1H),	6.56	(dd,	J=17.09,	10.61,	1H),	6.31	(dd,	J=17.05,	1.97,	1H),	5.73	
(dd,	J=10.68,	1.97,	1H),	3.76	(s,	2H),	3.65	(s,	2H),	3.22	(s,	2H),	2.68	(t,	J=5.09,	4H),	2.33	(s,	3H),	
2.24	(s,	3H).	13C	NMR	(500	MHz,	CDCl3)	δ	167.41,	165.65,	137.04,	135.43,	130.32,	128.66,	
127.23,	125.49,	123.89,	121.77,	62.21,	53,73,	53.27,	46.04,	42.26,	21.39,	17.50	
	
	
S1-12	N-((5-phenyl-1H-pyrazol-3-yl)methyl)acrylamide:	
(3-phenyl-1H-pyrazol-5-yl)methanamine	(50mg,	1eq,	0.287mmol)	was	dissolved	in	2mL	
acetonitrile.		TEA	(80uL,	2eq,	0.574mmol)	was	added	at	ambient	temperature.		The	reaction	
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was	cooled	to	0°C.		Acryloyl	chloride	(25uL,	1.1	eq,	0.316mmol)	was	added.		The	reaction	was	
quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.			
The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	
was	purified	by	flash	chromatography	on	silica	gel	(0-15%	dichloromethane:	methanol)	and	RP-
HPLC	(35-70%	gradient)	to	get	the	desired	product	(13mg,	20%	yield)	as	a	white	powder.	HRMS	
C13H14N3O	[M+H]+	expected	mass:	228.1137;	observed:	228.1145.	1H	NMR	(400	MHz,	MeOD)	δ	
7.69	(s,	2H),	7.41	(t,	J=6.96,	2H),	7.32	(t,	J=6.89,	1H),	6.57	(s,	1H),	6.28	(m,	2H),	5.69	(dd,	J=7.84,	
4.24,	1H),	4.50	(s,	2H).	
	
	
S1-13	(S)-1-(3-(2-(3,4-dihydroquinolin-1(2H)-yl)ethyl)piperidin-1-yl)prop-2-en-1-one:		
(S)-1-(2-(piperidin-3-yl)ethyl)-1,2,3,4-tetrahydroquinoline	(63.8mg,	1	eq,	0.227mmol)	was	
dissolved	in	2mL	acetonitrile.	TEA	(57uL,	2eq,	0.408mmol)	was	added	at	ambient	temperature.		
The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(18uL,	1	eq,	0.224	mmol)	was	added.		The	
reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	
temperature.			The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	
compound	was	purified	by	flash	chromatography	on	silica	gel	(5-95%	hexanes:	ethyl	acetate),	
followed	by	RP-HPLC	(45-95%	gradient)	to	get	the	desired	product	(2.1mg,	3%	yield)	as	an	
orange	solid.	HRMS	C19H27N2O	[M+H]	+	expected	mass:	299.2123;	observed:	299.2125.		1H	NMR	
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(400	MHz,	CDCl3)	δ	7.03	(m,	1H),	6.93	(m,	1H),	6.55	(m,	3H),	6.25	(d,	J=16.94,	1H),	5.65	(t,	
J=9.53,	1H),	4.45	(dd,	J=31.77,	12.64,	1H),	3.87	(d,	J=12.64,	1H),	3.32	(t,	J=6.24,	2H),	3.26	(m,	
2H),	3.08	(t,	J=12.11,	1H),	2.83	(t,	J=12.96,	1H),	2.74	(t,	J=6.24,	2H),	2.54	(t,	J=10.80,	1H),	1.94	
(m,	3H),	1.75	(d,	J=13.57,	1H),	1.47	(m,	3H),	1.26	(m,	1H).	
	
2	1-(4-(benzo[d]thiazol-2-ylamino)piperidin-1-yl)prop-2-en-1-one:	
N-(piperidin-4-yl)benzo[d]thiazol-2-amine	(58mg,	1	eq,	0.213	mmol)	was	dissolved	in	2mL	
acetonitrile	at	ambient	temperature.	TEA	(60uL,	2eq,	0.427mmol)	was	added	at	ambient	
temperature.		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(19uL,	1.1	eq,	0.235mmol)	was	
added.		The	reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	
at	ambient	temperature.			The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	
Na2SO4.		The	compound	was	purified	by	flash	chromatography	on	silica	gel	(0-15%	
dichloromethane:	methanol)	to	get	the	desired	product	(7mg,	11%yield)	as	a	yellow	oil.	
HRMS	
C15H18N3OS	[M+H]+	expected	mass:	288.1171;	observed:	288.1176.	1H	NMR	(400	MHz,	CDCl3)	δ	
7.58	(d,	J=8.06,	1H),	7.54	(d,	J=8.08,	1H),	7.30	(t,	J=8.07,	1H),	7.10	(t,	J=7.75,	1H),	5.17	(s,	1H),	
4.58	(s,	1H),	4.00	(s,	2H),	3.27	(t,	J=12.29,	1H),	2.97	(t,	J=11.96,	1H),	2.23	(m,	2H),	1.63	(s,	2H),	
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1.49	(s,	2H).	13C	NMR	(500	MHz,	CDCl3)	δ	165.63,	165.61,	152.44,	130.53,	128.25,	127.62,	
126.16,	122.04,	120.94,	119.22,	52.16,	44.66,	41.02,	33.07,	32.08.	
	
	
	
S1-14	(R)-N-((1-(3,5-dimethoxyphenyl)pyrrolidin-3-yl)methyl)acrylamide:	
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide(11mg,	1.4eq,	0.7mmol)		was	dissolved	in	1mL	
dimethylformamide	at	ambient	temperature.		The	reaction	was	cooled	to	0°C.		DIPEA	(44uL,	5	
eq,	0.25mmol),	and	then	hydroxybenzotriazole	(11mg,	1.4eq,	0.7mmol)	was	added.		Acrylic	acid	
(5uL,	1.4eq,	0.7mmol)	was	added	to	the	reaction,	and	was	stirred	for	30	minutes.	(R)-(1-(3,5-
dimethoxyphenyl)pyrrolidin-3-yl)methanamine	(12mg,	1	eq,	0.051mmol)	was	added	at	0°C.		
The	reaction	was	washed	with	5mL	saturated	NaCl.	The	product	was	extracted	with	ethyl	
acetate	(5mL	x	3)	and	dried	over	Na2SO4.		The	compound	was	purified	by	flash	chromatography	
on	silica	gel	(5-100%	hexanes:	ethyl	acetate)	to	get	the	desired	product	(2.3mg,	16%	yield)	as	a	
yellow	oil.		MS	C16H22N2O3	[M+H]+	expected:	291.1703,	observed:	291.1732.	1H	NMR	(400	MHz,	
CDCl3)	δ	6.30	(d,	J=16.73,	1H),	6.09	(dd,	J=16.54,	9.73,	1H),	5.89	(m,	1H),	5.74	(d,	J=1.95,	2H),	
5.67	(d,	J=9.73,	1H),	3.78	(s,	6H),	3.40	(m,	4),	3.28	(m,	1H),	3.04	(m,	1H),	2.59	(m,	1H),	2.29	(m,	
1H),	1.78	(m,	1H).	
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1	(1R)-2-acryloyl-N-(naphthalen-2-yl)cyclopentanecarboxamide:	
L-Proline-2-naphthylamide	hydrochloride	(55.5mg,	1	eq,	0.20mmol)	was	dissolved	in	2mL	
acetonitrile.	TEA	(58uL,	2eq,	0.414mmol)	was	added	at	ambient	temperature.		The	reaction	was	
cooled	to	0°C.		Acryloyl	chloride	(19uL,	1.1	eq,	0.228mmol)	was	added.		The	reaction	was	
quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.			
The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	
was	purified	by	flash	chromatography	on	silica	gel	(5-95%	hexanes:	ethyl	acetate)	to	get	the	
desired	product	(39.4mg,	67%yield)	as	a	white,	crystalline	solid.		
HRMS	
C18H18N2O2Na	[M+Na]+	expected	mass:	317.1266;	observed:	317.1271.	1H	NMR	(500MHz,	
CDCl3)	δ	10.02	(s,	1H),	8.23	(s,	1H),	7.73	(m,	3H),	7.45	(dd,	J=8.82,	1.98,	1H),	7.41	(t,	J=7.39,	1H),	
7.35	(t,	J=7.52,	1H),	6.52	(d,	J=6.38,	2H),	5.82	(t,	J=6.31,	1H),	4.94	(d,	J=7.67,	1H),	3.72	(t,	J=9.60,	
1H),	3.57	(m,	1H),	2.66	(dd,	J=12.48,	6.56,	1H),	2.22	(m,	1H),	2.09	(m,	1H),	1.88	(m,	1H).	13C	NMR	
(500MHz,	CDCl3)	δ	169.06,	166.74,	135.92,	133.97,	130.57,	129.63,	128.62,	127.99,	127.74,	
127.57,	126.37,	124.80,	120.21,	116.39,	60.99,	47.82,	26.54,	25.21.	
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S1-15	N-((6-chloro-7-methyl-1H-indol-2-yl)methyl)-N-methylacrylamide:	
6-chloro-2-methyl-1H-indol-2-y	methyl	methylamine	(50mg,	1eq,	0.24	mmol)	was	dissolved	in	
2mL	acetonitrile.		TEA	was	added	(67uL,	2eq,	0.48mmol)	was	added	at	ambient	temperature.		
The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(21uL,	1.1	eq,	0.26mmol)	was	added.		The	
reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	
temperature.			The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	
compound	was	purified	by	flash	chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate)	
to	get	the	desired	product	(14.1mg,	22%yield),	as	an	orange	oil.	HRMS	C14H15ClN2ONa	[M+Na]+	
expected	mass:	285.0771;	observed:	285.0776.		1H	NMR	(400	MHz,	CDCl3)	δ	7.31	(d,	J=8.45,	1H)	
7.08	(d,	J=8.49,	1H)	6.57	(dd,	J=16.73,	10.30,	1H),	6.41	(dd,	J=16.73,	1.93,	1H),	6.38	(d,	J	=	2.11,	
1H),	5.77	(dd,	J=10.45,	1.83,	1H),	4.60	(s,	2H)	3.10	(s,	3H),	2.49	(s,	3H).	
	
	
S1-16	4-acryloyl-N-(m-tolyl)piperazine-1-carboxamide:	
N-(m-tolyl)piperazine-1-carboxamide	(35.6mg,	1	eq,	0.162	mmol)	was	dissolved	in	2mL	ACN.	
TEA	was	added	(45uL,	2	eq,	0.324	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	
(13uL,	1	eq,	0.162	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	NaHCO3	
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and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	extracted	with	ethyl	
acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	twice	by	flash	
chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate	(to	get	the	desired	product	
(3.7mg,	8%	yield)	as	a	yellow	powder.	HRMS	C15H20N3O2	[M+H]+	expected	mass:	274.1556;	
observed:	274.1563.	1H	NMR	(500	MHz,	CDCl3)	δ	7.21	(s,	1H),	7.18	(t,	J=7.88,	1H),	7.11	(d,	
J=8.00,	1H),	6.88	(d,	J=7.70,	1H),	6.57	(dd,	J=16.79,	10.37,	1H),	6.35	(dd,	J=16.85,	1.86),	6.34	(s,	
1H),	5.76	(dd,	J=10.53,	1.83,	1H),	3.64	(m,	8H),	2.33	(s,	3H).	13C	NMR	(500	MHz,	CDCl3)	δ	167.72,	
157.91,	140.58,	139.48,	129.47,	128.96,	128.76,	125.03,	122.82,	119.30,	46.70,	45.19,	44.93,	
43.00,	21.55.	
	
	
S1-17	N-(2-(naphthalen-2-yl)-2-oxoethyl)acrylamide:	
2-(naphthalen-2-yl)-2-oxoethanaminium	chloride	(25.3mg,	1	eq,	0.114	mmol)	was	dissolved	in	
2mL	ACN.	TEA	was	added	(32uL,	2	eq,	0.228	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	
chloride	(9uL,	1	eq,	0.114	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	
NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	extracted	
with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate),	followed	by	RP-HPLC	(25-90%	
gradient)	to	get	the	desired	product	(3.7mg,	14%	yield)	as	a	white	solid.	HRMS	C15H14NO2	
[M+H]+	expected	mass:	240.1025;	observed:	240.1029.	1H	NMR	(500	MHz,	CDCl3)	δ	8.80	(d,	
J=8.66,	1H),	8.08	(d,	J=8.23,	1H),	8.04	(d,	J=7.35,	1H),	7.90	(d,	J=8.23,	1H),	7.65	(t,	J=7.66,	1H),	
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7.58(t,	J=7.58,	1H),	7.54	(d,	J=7.66,	1H),	6.78	(s,	1H),	6.39	(dd,	J=17.15,1.48,	1H),	6.29	(dd,	
J=17.02,	10.12,	1H),	5.75	(dd,	J=10.18,	1.38,	1H).	4.91	(s,	2H).	
	
	
S1-18	4-(acrylamidomethyl)-N-(pyridin-4-yl)benzamide:	
(4-(pyridin-4-ylcarbamoyl)phenyl)methanaminium	chloride	hydrochloride	(25.6mg,	1	eq,	0.085	
mmol)	was	dissolved	in	2mL	acetonitrile.		TEA	was	added	(75	uL,	6	eq,	0.51	mmol).		The	
reaction	was	cooled	to	0°C.		Acryloyl	chloride	(7uL,	1	eq,	0.085mmol)	was	added.	The	reaction	
was	quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	
temperature.			The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	
compound	was	purified	by	flash	chromatography	on	silica	gel	(0-15%	dichloromethane:	
methanol)	followed	by	RP-HPLC	with	a	gradient	of	25-90%	to	get	the	desired	product	(1.1mg,	
5%	yield)	as	a	white	solid.	HRMS	C16H16N3O2	[M+H]+	expected	mass:	282.1243;	observed:	
282.1235.		1H	NMR	(500MHz,	CD3OD)	δ	8.44	(d,	J	=	6.3,	2H),	7.94(d,	J=8.45,	2H),	7.84	(d,	J=6.3,	
2H),	6.32	(dd,	J	=	17.19,	9.16,	1H)	6.27	(dd,	J	=	17.19,	2.87,	1H),	5.71	(dd,	J	=	9.20,	2.83),	4.54	(s,	
2H).	
	
S1-19	N-((6-(4-fluorophenoxy)pyridin-3-yl)methyl)acrylamide:	
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(6-(4-fluorophenoxy)pyridin-3-yl)methanamine	hydrochloride	(23.0mg,	1	eq,	0.105	mmol)	was	
dissolved	in	2mL	ACN.	TEA	was	added	(29uL,	2	eq,	0.211	mmol).		The	reaction	was	cooled	to	
0°C.		Acryloyl	chloride	(9uL,	1	eq,	0.105	mmol)	was	added.	The	reaction	was	quenched	with	5mL	
saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	
extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate),	followed	by	RP-HPLC	(25-90%	
gradient)	to	get	the	desired	product	(0.8	mg,	3%	yield),	as	an	opaque	oil.	HRMS	C15H14FN2O2	
[M+H]+	expected	mass:	273.1039;	observed:	273.1039.	1H	NMR	(400	MHz,	CDCl3)	δ	8.09	(d,	
J=2.52,	1H),	7.69	(dd,	J=8.47,	2.52,	1H),	6.89	(d,	J=8.47),	7.08	(d,	J=6.47,	4H),	6.33	(dd,	
J=16.99,1.20,	1H),	6.09	(dd,	J=16.99,	10.26,	1H),	5.81	(s,	1H),	5.70	(dd,	J=10.38,	1.21),	4.49	(s,	
1H),	4.47	(s,	1H).	
	
	
S1-20	N-(2-(1H-indol-3-yl)-2-(thiophen-2-yl)ethyl)acrylamide:	
2-(1H-indol-3-yl)-2-(thiophen-2-yl)ethanamine	(25.1mg,	1	eq,	0.104	mmol)	was	dissolved	in	2mL	
ACN.	TEA	was	added	(30uL,	2	eq,	0.208	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	
chloride	(8uL,	1	eq,	0.104	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	
NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	extracted	
with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	
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chromatography	on	silica	gel	(5-100%	hexanes:EtOAC),	followed	by	RP-HPLC	(25-90%	gradient)	
to	get	the	desired	product	(4.7mg,	15%	yield)	as	an	opaque	oil.	HRMS	C17H16N2OS	[M-H]-	
expected	mass:	295.0911,	observed:	295.0901.	1H	NMR	(500	MHz,	CDCl3)	δ	7.57	(d,	J=8,	1H),	
7.38	(d,	J=8.07,	1H),	7.21	(t,	J=7.62,	1H),	7.18	(m,	1H),	7.13	(d,	J=2.37,	1H),	7.09	(t,	J=7.62,	1H),	
6.96	(m,	2H),	4.77	(t,	J=	7.22,	1H),	4.14	(m,	1H),	3.97	(m,	1H).	13C	NMR	(500	MHz,	CDCl3)	δ	
165.63,	146.15,	136.59,	130.86,	126.95,	126.84,	126.53,	124.93,	124.22,	122.62,	122.04,	119.93,	
119.57,	116.70,	111.43,	45.03,	38.29.	
	
	
S1-21	N-(1-(3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acrylamide:	
1-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]ethan-1-amine	hydrochloride	(26.8mg,	1	eq,	0.105	
mmol)	was	dissolved	in	2mL	ACN.	TEA	was	added	(30uL,	2	eq,	0.21	mmol).		The	reaction	was	
cooled	to	0°C.		Acryloyl	chloride	(9uL,	1	eq,	0.105	mmol)	was	added.	The	reaction	was	
quenched	with	5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	
The	reaction	was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	
was	purified	by	flash	chromatography	on	silica	gel	(5-100%	hexanes:EtOAC),	followed	by	RP-
HPLC	(25-90%	gradient)	to	get	the	desired	product	(5.1mg,	20%	yield),	as	an	opaque	oil.	HRMS	
C14H16N3O3	[M+H]+	expected	mass:	274.1192;	observed:	274.1198.	1H	NMR	(500	MHz,	CDCl3)	δ	
7.97	(dd,	J=7.68,	1.76,	1H),	7.49	(m,	1H),	7.07	(dd,	7.69,	14.81,	1H),	6.37	(dd,	J=17.05,	1.05,	1H),	
6.18	(dd,	J=17.00,	10.38,	1H),	5.74	(J=10.35,	1.05,	1H),	5.59	(q,	J=7.12,	1H),	3.97	(s,	3H),	1.68	(d,	
J=7.09,	3H).	
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S1-22	N-methyl-N-(1-(quinazolin-4-yl)piperidin-4-yl)acrylamide:	
N-methyl-1-(quinazolin-4-yl)piperidin-4-amine	(53.7mg,	1	eq,	0.222	mmol)	was	dissolved	in	2mL	
ACN.	TEA	was	added	(62uL,	2	eq,	0.443	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	
chloride	(18uL,	1	eq,	0.222	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	
NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	extracted	
with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	
chromatography	on	silica	gel	(0-15%	DCM:methanol),	followed	by	RP-HPLC	(25-55%	gradient)	to	
get	the	desired	product	(3.1mg,	5%	yield),	as	an	opaque	oil.	HRMS	C17H21N4O	[M+H]+	expected	
mass:	297.1715;	observed:	297.1717.	1H	NMR	(500	MHz,	MeOD)	δ	8.59	(d,	J=4.77,	1H),	8.48	(s,	
1H),	8.06	(d,	J=8.41,	1H),	7.82	(m,	1H),	7.57	(m,	1H),	6.90	(dd,	16.90,	10.90,	1H),	6.75	(dd,	16.88,	
10.50,	1H),	6.23	(dd,	J=16.91,	10.36,	1H),	5.76	(dd,	10.65,	19.7,	1H),	4.77	(m,	1H),	4.57	(m,	1H),	
4.28	(m,	1H),	3.03	(s,	1H),	2.93	(s,	1H),	2.09	(m,	3H),	1.83	(m,	2H).	
	
	
S1-23	1-(4-(5-methyl-4-phenyloxazol-2-yl)piperidin-1-yl)prop-2-en-1-one:	
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5-methyl-4-phenyl-2-(piperidin-4-yl)oxazole	(27.0mg,	1eq,	0.111	mmol)	was	dissolved	in	2mL	
CAN.		TEA	was	added	(31uL,	2eq,	0.223	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	
chloride	(9uL,	1	eq,	0.111	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	
NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.		The	reaction	was	extracted	
with	ethyl	acetate	(5mL	x	3),	and	dried	over	Na2SO4.	The	compound	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%	hexanes:	ethyl	acetate),	followed	by	RP-HPLC	(45-95%	
gradient)	to	get	the	desired	product	(3.1mg,	5%	yield),	as	a	white	solid.	HRMS	C18H21N2O2	
[M+H]+	expected	mass:	297.1603;	observed:	297.1617.	1H	NMR	(400	MHz,	CDCl3)	δ	7.62	(d,	
J=8.06,	2H),	7.41	(t,	J=7.52,	2H),	7.29	(t,	J=	7.42,	1H),	6.60	(dd,	J=16.87,	10.59,	1H),	6.28	(dd,	
J=16.82,	1.90,	1H),	5.70	(dd,	J=10.56,	1.84,	1H),	3.12	(m,	1H),	3.08	(m,	2H),	2.50	(s,	3H),	2.13	(m,	
2H),	1.89	(m,	2H),	1.65	(m,	2H).	
	
	
	
S1-24	N-((4-(6-methyl-1H-benzo[d]imidazol-2-yl)cyclohexyl)methyl)acrylamide:	
	(4-(6-methyl-1H-benzo[d]imidazol-2-yl)cyclohexyl)methanamine	(50.8mg,	1	eq,	0.209mmol)	
was	dissolved	in	2mL	ACN.	TEA	was	added	(174uL,	6	eq,	1.254	mmol).		The	reaction	was	cooled	
to	0°C.		Acryloyl	chloride	(17uL,	1	eq,	0.209	mmol)	was	added.	The	reaction	was	quenched	with	
5mL	saturated	NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	
was	extracted	with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	
flash	chromatography	on	silica	gel	(0-15%	hexanes:EtOAC),	followed	by	RP-HPLC	(5-95%	
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gradient)	to	get	the	desired	product	(4.6mg,	7%	yield),	as	a	white	solid.	HRMS	C18H24N3O	
[M+H]+	expected	mass:	298.1919;	observed:	298.1925.	1H	NMR	(500	MHz,	MeOD)	δ	7.39	(d,	
J=8.35,	1H),	7.31	(s,	1H),	7.07	(d,	J=8.35,	1H),	6.27	(dd,	J=17.05,	9.41,	1H),	6.22	(dd,	J	=	17.05,	
2.68,	1H),	5.66	(dd,	J=9.41,	2.64,	1H),	3.18	(d,	J=6.80,	2H),	2.89	(m,	1H),	2.45	(s,	3H),	2.16	(d,	
J=13.01,	2H),	1.76	(d,	J=13.01,	2H),	1.69	(m,	2H),	1.66	(m,	1H),	1.19	(d,	2H).	
	
	
S1-25	1-(3-((2-chlorobenzyl)oxy)pyrrolidin-1-yl)prop-2-en-1-one:		
3[(2-chlorobenzyl)oxy]pyrrolidine	hydrochloride	(50.3mg,	1	eq,	0.203mmol)	was	dissolved	in	
2mL	ACN.	TEA	was	added	(57uL,	2	eq,	0.405	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	
chloride	(16uL,	1	eq,	0.203	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	
NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	extracted	
with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%	hexanes:EtOAc),	followed	by	RP-HPLC	(45-95%	gradient)	
to	get	the	desired	product	(1.5mg,		3%	yield),	as	an	opaque	oil.	HRMS	C14H17ClNO2	[M+H]+	
expected	mass:	266.0948;	observed:	266.0959.	1H	NMR	(500	MHz,	MeOD,	1:1	rotamers)	δ	7.48	
(m,	1H),	7.38	(m,	1H),	7.29	(m,	2H),	(6.63	+	6.58)	(rotamers	dd,	J=16.83,	10.51,	1H),	(6.27+6.26)	
(dd,	rotamers,	J=16.86,	1.88,	1H),	(5.75+5.73)	(rotamers,	dd,	J=10.46,	1.89,	1H),	4.65	(m,	2H),	
4.32	(m,	1H),	3.75	(m,	2H),	3.68	(m,	1H),	3.56	(m,	1H),	2.14	(m,	2H).	
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S1-26	N-(1-(2-methylpyrimidin-4-yl)piperidin-4-yl)acrylamide:	
1-(2-methylpyrimidin-4-yl)piperidin-4-amine	(34.1mg,	1	eq,	0.177mmol)	was	dissolved	in	2mL	
ACN.	TEA	was	added	(50uL,	2	eq,	0.355	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	
chloride	(14uL,	1	eq,	0.177	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	
NaHCO3	and	left	stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	extracted	
with	ethyl	acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	flash	
chromatography	on	silica	gel	(0-15%	DCM:methanol),	followed	by	RP-HPLC	(20-55%	gradient)	to	
get	the	desired	product	(5.1mg,	12%	yield),	as	a	white	solid.	HRMS	C13H19N4O	[M+H]+	expected	
mass:	247.1559;	observed:	247.1561.1H	NMR	(500	MHz,	MeOD)	δ	8.32	(s,	1H),	8.04	(d,	J=7.15,	
1H),	6.83	(d,	J=7.14,	1H),	6.58	(dd,	J=6.58,	5.52,	1H),	6.24	(m,	2H),	4.10	(m,	1H),	3.26	(m,	2H),	
2.50	(s,	3H),	2.04	(m,	2H),	1.51	(m,	2H).	
	
	
S1-27	1-(4-(2-(o-tolyl)acetyl)piperazin-1-yl)prop-2-en-1-one:	
1-(piperazin-1-yl)-2-(o-tolyl)ethanone	(67mg,	1	eq,	0.307mmol)	was	dissolved	in	2mL	ACN.	TEA	
was	added	(86uL,	2	eq,	0.614	mmol).		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(25uL,	1	
eq,	0.307	mmol)	was	added.	The	reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	
stirring	for	15	minutes	at	ambient	temperature.	The	reaction	was	extracted	with	ethyl	acetate	
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(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	RP-HPLC	(5-95%	gradient)	to	get	
the	desired	product	8.4mg,	10%	yield),	as	an	opaque	oil.	HRMS	C16H21N2O2	[M+H]+	expected	
mass:	273.1603;	observed:	273.1608.1H	NMR	(400	MHz,	CDCl3)	δ	7.15	(m,	4H),	6.53	(m,	1H),	
6.31	(d,	J=16.75,	1H),	5.73	(d,	J=9.76,	1H),	3.71	(s,	4H),	3.57	(s,	2H),	3.43	(s,	2H),	2.29	(s,	3H).	
	
	
5	(R)-1-acryloyl-N-(naphthalen-2-yl)pyrrolidine-2-carboxamide:	
N-Boc-L-proline	(100mg,	0.465	mmol,	1	eq)	was	dissolved	in	1mL	DMF	and	DIPEA	(324uL,	4	eq,	
1.86	mmol).	The	solution	was	cooled	to	0°C	and	HATU	(194mg,	0.511	mmol,	1.1	eq)	was	added.	
The	reaction	was	stirred	for	20	minutes	followed	by	an	addition	of	2-amino-naphthalene	(73mg,	
0.511	mmol,	1.1eq).	After	2-5	hours,	the	solution	was	diluted	with	10mL	brine	and	extracted	
with	EtOAc	(3x10mL).		The	combined	organic	layers	were	dried	over	Na2SO4,	filtered,	and	
evaporated	to	dryness	in	vacuo.	The	residue	was	purified	by	flash	chromatography	on	silica	gel	
(5-100%)	EtoAC:hexanes	to	afford	the	desired	product,	(R)-tert-butyl	2-(naphthalen-2-
ylcarbamoyl)pyrrolidine-1-carboxylate.	
The	product	was	dissolved	in	2mL	DCM.		The	mixture	was	cooled	to	0°C	and	1mL	TFA	was	
added.	When	the	reaction	was	complete,	the	mixture	was	quenched	using	5mL	NaHCO3	and	
the	product	was	extracted	with	3x3mL	DCM.		The	crude	product,	(R)-N-(naphthalen-2-
yl)pyrrolidine-2-carboxamide,	was	used	without	further	purification.			
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	(R)-N-(naphthalen-2-yl)pyrrolidine-2-carboxamide	(38.6	mg,	0.161	mmol,	1	eq)	was	dissolved	in	
2mL	ACN	to	which	TEA	(45uL,	0.321	mmol,	2	eq)	was	added.		The	solution	was	cooled	to	0°C	
upon	which	acryloyl	chloride	(14uL,	0.177	mmol,	1.1	eq)	was	added.		After	30	minutes,	the	
reaction	was	quenched	with	5mL	NaHCO3.		The	solution	was	left	to	stir	for	15	minutes.		The	
mixture	was	extracted	with	ethyl	acetate	(3x5mL).		The	combined	organic	layers	were	dried	
with	Na2SO4,	filtered,	and	evaporated	in	vacuo.		The	residue	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%)	hexanes:	ethyl	acetate	to	get	the	desired	product	(R)-1-
acryloyl-N-(naphthalen-2-yl)pyrrolidine-2-carboxamide	(14.6mg,	31%	yield),	as	an	opaque	oil.	
	
HRMS	C18H18N2O2Na	[M+Na]+	expected	mass:	317.1266;	observed:	317.1267.	1H	NMR	(400	
MHz,	CDCl3)	δ	9.99	(s,	1H),	8.23	(s,	1H),	7.74	(m,	3H),	7.47	(dd,	J=8.84,	2.12,	1H),	7.42	(t,	J=6.82,	
1H),	7.36	(t,	J=7.44,	1H).	6.52	(J=6.10,	2H),	5.82	(t,	J=6.10,	1H),	4.94	(d,	J=7.82,	1H),	3.72	(m,	1H),	
3.58	(m,	1H),	2.68	(dd,	J=12.62,	6.50,	1H),	2.21	(m,	1H),	2.09	(m,	1H),	1.86	(m,	1H).	13C	NMR	
(500	MHz,	CDCl3)	δ	169.01,	166.81,	135.92,	134.00,	130.60,	129.68,	128.66,	127.98,	127.76,	
127.60,	126.42,	124.84,	120.24,	116.42,	60.99,	47.84,	26.46,	25.23.	
	
	
6	(2S,4R)-1-acryloyl-4-hydroxy-N-(naphthalen-2-yl)pyrrolidine-2-carboxamide:	
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4-hydroxy-N-(naphthalen-2-yl)pyrrolidine-2-carboxamide	(50mg,	1	eq,	0.195	mmol)	was	
dissolved	in	4mL	mixture	of	1:1	ACN:DMF.	TEA	(164uL,	1.170	mmol,	6	eq)	was	added.		The	
solution	was	cooled	to	0°C	upon	which	acryloyl	chloride	(17uL,	0.215	mmol,	1.1	eq)	was	added.		
After	30	minutes,	the	reaction	was	quenched	with	5mL	NaHCO3.		The	solution	was	left	to	stir	
for	15	minutes.		The	mixture	was	extracted	with	ethyl	acetate	(3x5mL).		The	combined	organic	
layers	were	dried	with	Na2SO4,	filtered,	and	evaporated	in	vacuo.		The	residue	was	purified	by	
flash	chromatography	on	silica	gel	(5-100%)	hexanes:	ethyl	acetate	to	get	the	desired	product	
(2S,4R)-1-acryloyl-4-hydroxy-N-(naphthalen-2-yl)pyrrolidine-2-carboxamide	(10.5mg,	17%	
yield),	as	a	white	solid.	MS	
HRMS	
C18H18N2O3Na	[M+Na]+	expected	mass:	333.1215;	observed:	333.1219.	1H	NMR	(400	MHz,	
(CD3)2SO,	9:1	rotamers)	δ	(10.28+10.41)	(s,	1H),	8.29	(s,	1H),	7.83	(m,	3H),	7.59	(d,	J=8.85,	1H),	
7.46	(t,	J=6.76,	1H),	7.39	(t,	6.90,	1H),	(6.63	+	6.36)	(dd,	J=16.67,	10.05,	1H),	6.13	(J=16.62,	2.08,	
1H),	(5.71	+	5.64)	(J=10.15,	2.28,	1H),	5.20	(d,	J=3.56,	1H),	(4.62	+	4.76)	(t,	J=7.93,	1H),	(4.43	+	
4.35)	(s,	1H),	3.76	(dd,	J=10.69,	4.49,	1H),	3.58	(d,	J=10.69,	1H),	2.16	(m,	1H),	1.99	(m,	1H).	13C	
NMR	(500	MHz,	MeOD)	δ	172.94,	167.25,	137.18,	135.21,	132.19,	129.87,	129.52,	128.88,	
128.59,	127.46,	126.05,	121.29,	121.13,	118.06,	71.22,	61.38,	56.94,	39.18.	
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7	(S)-1-acryloyl-N-(6-bromonaphthalen-2-yl)pyrrolidine-2-carboxamide:	
N-Boc-L-proline	(100mg,	0.465	mmol,	1	eq)	was	dissolved	in	1mL	DMF.	The	solution	was	cooled	
to	0°C	and	HATU	(582mg,	1.533	mmol,	3.3	eq)	was	added.	The	reaction	was	stirred	for	15	
minutes	followed	by	an	addition	of	2-amino-6-bromo-naphthalene	(114mg,	0.511	mmol,	
1.1eq).	After	6	hours,	the	solution	was	diluted	with	10mL	brine	and	extracted	with	EtOAc	
(3x10mL).		The	combined	organic	layers	were	dried	over	Na2SO4,	filtered,	and	evaporated	to	
dryness	in	vacuo.	The	residue	was	purified	by	flash	chromatography	on	silica	gel	(5-100%)	
EtoAC:hexanes	to	afford	the	desired	product,	(2S,4R)-tert-butyl-2-((6-bromonaphthalen-2-
yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate,	(217mg,	yield	quantitative).	
The	product	was	dissolved	in	2mL	DCM.		The	mixture	was	cooled	to	0°C	and	1mL	TFA	was	
added.	When	the	reaction	was	complete,	the	mixture	was	quenched	using	5mL	NaHCO3	and	
the	product	was	extracted	with	3x3mL	DCM.		The	crude	product,	(S)-N-(6-bromonaphthalen-2-
yl)pyrrolidine-2-carboxamide	was	used	without	further	purification.			
(S)-N-(6-bromonaphthalen-2-yl)pyrrolidine-2-carboxamide	(83.8	mg,	0.263	mmol,	1	eq)	was	
dissolved	in	2mL	ACN	to	which	TEA	(73uL,	0.525	mmol,	2	eq)	was	added.		The	solution	was	
cooled	to	0°C	upon	which	acryloyl	chloride	(8uL,	0.104	mmol,	1.1	eq)	was	added.		After	30	
minutes,	the	reaction	was	quenched	with	5mL	NaHCO3.		The	solution	was	left	to	stir	for	15	
minutes.		The	mixture	was	extracted	with	ethyl	acetate	(3x5mL).		The	combined	organic	layers	
were	dried	with	Na2SO4,	filtered,	and	evaporated	in	vacuo.		The	residue	was	purified	by	flash	
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chromatography	on	silica	gel	(5-100%)	hexanes:	ethyl	acetate,	followed	by	RP-HPLC	gradient	of	
5-95%	to	afford	the	desired	product	(S)-1-acryloyl-N-(6-bromonaphthalen-2-yl)pyrrolidine-2-
carboxamide	(14.2mg,	14%yield),	as	an	opaque	oil.		
	1H	
NMR	(400	MHz,	CDCl3).	HRMS	C18H18BrN2O2	[M+H]+	expected	mass:	373.0552;	observed:	
373.0553.	δ	10.10	(s,	1H),	8.20	(s,	1H),	7.86	(s,	1H),	7.61	(d,	J=8.78,	1H),	7.56	(d,	J=8.78,	1H),		
7.44	(m,	2H),		6.52	(dd,	J=6.03,	1.41,	2H),	5.83	(dd,	J=6.71,	5.44,	1H),	4.94	(d,	J=7.68,	1H),	3.73	
(m,	1H),	3.60	(m,	1H),	2.64	(m,	1H),	2.23	(m,	1H),	2.10	(m,	1H),	1.90	(m,	1H)	13C	NMR	(400	MHz,	
CDCl3)	δ	169.23,	166.75,	136.38,	132.42,	131.52,	129.74,	129.70,	129.59,	129.38,	127.97,	
127.70,	121.18,	118.54,	116.22,	61.04,	47.89,	26.64,	25.24.	
	
	
8	((S)-1-acryloyl-N-(3-hydroxynaphthalen-2-yl)pyrrolidine-2-carboxamide:	
N-Boc-L-proline	(100mg,	0.465	mmol,	1	eq)	was	dissolved	in	1mL	DMF.	The	solution	was	cooled	
to	0°C	and	HATU	(194mg,	0.511	mmol,	1.1	eq)	was	added.	The	reaction	was	stirred	for	15	
minutes	followed	by	an	addition	of	3-amino-2-naphthol	(81mg,	0.511	mmol,	1.1eq).	After	12-18	
hours,	the	solution	was	diluted	with	10mL	brine	and	extracted	with	EtOAc	(3x10mL).		The	
combined	organic	layers	were	dried	over	Na2SO4,	filtered,	and	evaporated	to	dryness	in	vacuo.	
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The	residue	was	purified	by	flash	chromatography	on	silica	gel	(5-100%)	hexanes:	ethyl	acetate	
to	afford	the	desired	product,	(S)-tert-butyl	2-((3-hydroxynaphthalen-2-
yl)carbamoyl)pyrrolidine-1-carboxylate,	(27.3mg,	19%	yield).	
The	product	was	dissolved	in	2mL	DCM.		The	mixture	was	cooled	to	0°C	and	1mL	TFA	was	
added.	When	the	reaction	was	complete,	the	mixture	was	quenched	using	5mL	NaHCO3	and	
the	product	was	extracted	with	3x3mL	DCM.		The	crude	product,	((S)-N-(3-hydroxynaphthalen-
2-yl)pyrrolidine-2-carboxamide,	was	used	without	further	purification.			
(S)-N-(3-hydroxynaphthalen-2-yl)pyrrolidine-2-carboxamide	(24.3	mg,	0.095	mmol,	1	eq)	was	
dissolved	in	3mL	ACN	to	which	TEA	(80uL,	0.570	mmol,	6	eq)	was	added.		The	solution	was	
cooled	to	0°C	upon	which	acryloyl	chloride	(8uL,	0.104	mmol,	1.1	eq)	was	added.		After	30	
minutes,	the	reaction	was	quenched	with	5mL	NaHCO3.		The	solution	was	left	to	stir	for	15	
minutes.	The	mixture	was	extracted	with	ethyl	acetate	(3x5mL).		The	combined	organic	layers	
were	dried	with	Na2SO4,	filtered,	and	evaporated	in	vacuo.		The	residue	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%)	hexanes:	ethyl	acetate,	followed	by	RP-HPLC	gradient	of	
5-95%	to	afford	the	desired	product	((S)-1-acryloyl-N-(3-hydroxynaphthalen-2-yl)pyrrolidine-2-
carboxamide	(1.7mg,	6%	yield),	as	a	white	powder.		
	
HRMS	C18H18N2O3Na	[M+Na]+	expected	mass:	333.1215;	observed:	333.1223.	1H	NMR	(400	
MHz,	CDCl3)	δ	10.21	(s,	1H),	7.83	(s,	1H),	7.65	(d,	J=7.99,	1H),	7.63	(d,	J=7.99,	1H),	7.32	(m,	3H),	
6.54	(d,	J=5.93,	2H),	5.85	(t,	J=5.92,	1H),	5.02	(d,	J=7.51,	1H),	3.76	(t,	J=9.13,	1H),	3.63	(q,	J=9.06,	
1H),	2.66	(q,	J=6.21,	1H),	2.24	(m,	1H),	2.13	(m,	1H),	1.95	(m,	1H).	13C	NMR	(500	MHz,	CDCl3)	δ	
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170.47,	167.06,	147.27,	132.54,	130.28,	128.60,	127.75,	127.72,	127.29,	126.17,	125.14,	124.06,	
119.90,	113.32,	60.72,	47.92,	26.77,	25.28.	
	
9	(2S,4R)-1-acryloyl-N-(6-bromonaphthalen-2-yl)-4-hydroxypyrrolidine-2-carboxamide:		
Trans-N-(tert-Butoxycarbonyl)-4-hydroxy-L-proline	(100mg,	0.433	mmol,	1	eq)	was	dissolved	in	
1mL	DMF.	The	solution	was	cooled	to	0°C	and	HATU	(329mg,	0.865mmol,	2	eq)	was	added.	The	
reaction	was	stirred	for	15	minutes	followed	by	an	addition	of	2-amino-6-bromo-naphthalene	
(106mg,	0.476	mmol,	1.1eq).	DMAP	(5mg,	0.0433mmol,	0.1	eq)	was	added.	After	heating	the	
solution	to	50°C	for	6	hours,	the	solution	was	diluted	with	10mL	brine	and	extracted	with	ethyl	
acetate	(3x10mL).		The	combined	organic	layers	were	dried	over	Na2SO4,	filtered,	and	
evaporated	to	dryness	in	vacuo.	The	residue	was	purified	by	flash	chromatography	on	silica	gel	
(5-100%)	hexanes:	ethyl	acetate	to	afford	the	desired	product,	(2S,4R)-tert-butyl	2-((6-
bromonaphthalen-2-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate	(199.8mg,	yield	
quantitative).	
The	product	was	dissolved	in	2mL	DCM.		The	mixture	was	cooled	to	0°C	and	1mL	TFA	was	
added.	After	5	hours,	the	solvent	and	excess	TFA	was	removed	in	vacuo	with	3x	5mL	toluene.	
The	crude	product,	(2S,4R)-tert-butyl	2-((6-bromonaphthalen-2-yl)carbamoyl)-4-
hydroxypyrrolidine-1-carboxylate,	was	used	without	further	purification.			
(2S,4R)-tert-butyl	2-((6-bromonaphthalen-2-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate	
(37.3	mg,	0.086	mmol,	1	eq)	was	dissolved	in	2mL	ACN	to	which	TEA	(24uL,	0.172	mmol,	2	eq)	
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was	added.		The	solution	was	cooled	to	0°C	upon	which	acryloyl	chloride	(8uL,	0.094	mmol,	1.1	
eq)	was	added.		After	30	minutes,	the	reaction	was	quenched	with	5mL	NaHCO3.		The	solution	
was	left	to	stir	for	15	minutes.		The	mixture	was	extracted	with	ethyl	acetate	(3x5mL).		The	
combined	organic	layers	were	dried	with	Na2SO4,	filtered,	and	evaporated	in	vacuo.		The	
residue	was	purified	by	flash	chromatography	on	silica	gel	(5-90%)	hexanes:	ethyl	acetate	to	
afford	the	desired	product	(2S,4R)-1-acryloyl-N-(6-bromonaphthalen-2-yl)-4-
hydroxypyrrolidine-2-carboxamide	(8.7mg,	26%	yield),	as	a	white	powder.		
HRMS	
C18H17BrN2O3Na	[M+Na]+	expected	mass:	411.032;	observed:	411.0333.	1H	NMR	(400	MHz,	
(CD3)2SO,	4:1	rotamers)	δ	(10.36+10.48)	(s,	1H),	8.32	(s,	1H),	8.12	(s,	1H),	7.86	(d,	J=8.77,	1H),	
7.77	(d,	J=8.77,	1H),	7.63	(dd,	J=8.86,	2.05,	1H),	7.57	(dd,	J=8.81,	1.98,	1H),		(6.63+6.35)	(dd,	
J=16.73,10.30,	1H),	6.13	(dd,	J=16.77,	2.05,	1H),	(5.71	+	5.64)	(dd,	J=10.38,	2.16,	1H),	(5.20	+	
5.14)	(d,	J=3.38,	1H),	(4.61+4.78)	(t,	J=7.94,	1H),	(4.43	+	4.34)	(s,	1H),	3.76	(dd,	J=10.77,	4.23,	
1H),	3.58	(d,	J=10.94,	1H),	2.15	(m,	1H),	1.99	(m,	1H).	13C	NMR	(500	MHz,	(CD3)2SO)	δ	170.87,	
163.66,	137.25,	136.70,	131.95,	130.80,	129.52,	129.41,	129.32,	127.65,	127.38,	120.99,	117.24,	
115.06,	68.92,	59.45,	55.40,	37.99.	
	
10	(2S,3R)-1-acryloyl-N-(6-bromonaphthalen-2-yl)-3-hydroxypyrrolidine-2-carboxamide:	
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N-boc-cis-3-hydroxy-L-proline	(57mg,	0.248	mmol,	1.1eq)	was	dissolved	in	2mL	pyridine.	The	
solution	was	cooled	to	0°C	and	HATU	(171mg,	2	eq,	0.450mmol)	was	added.	The	reaction	was	
stirred	for	15	minutes	followed	by	an	addition	of	2-amino-6-bromo-naphthalene	(50mg,	0.225	
mmol,	1eq).	After	heating	the	solution	to	70°C	in	a	reflux	condenser	for	2.5	hours,	the	solution	
was	diluted	with	10mL	brine	and	extracted	with	ethyl	acetate	(3x10mL).		The	combined	organic	
layers	were	dried	over	Na2SO4,	filtered,	and	evaporated	to	dryness	in	vacuo.	The	residue	was	
purified	by	flash	chromatography	on	silica	gel	(5-100%)	hexanes:	ethyl	acetate	to	afford	the	
desired	product(2S,3R)-tert-butyl	2-((6-bromonaphthalen-2-yl)carbamoyl)-3-
hydroxypyrrolidine-	1-carboxylate	(60.5mg,	62%	yield).		
The	product	was	dissolved	in	2mL	DCM.		The	mixture	was	cooled	to	0°C	and	1mL	TFA	was	
added.	After	5	hours,	the	solvent	and	excess	TFA	was	removed	in	vacuo	with	3x	5mL	toluene.	
The	crude	product,	(2S,3R)-N-(6-bromonaphthalen-2-yl)-3-hydroxypyrrolidine-2-carboxamide,	
was	used	without	further	purification.			
(2S,3R)-N-(6-bromonaphthalen-2-yl)-3-hydroxypyrrolidine-2-carboxamide	(53.2	mg,	0.159	
mmol,	1	eq)	was	dissolved	in	2mL	ACN	to	which	TEA	(44uL,	0.318	mmol,	2	eq)	was	added.		The	
solution	was	cooled	to	0°C	upon	which	acryloyl	chloride	(13uL,	0.159	mmol,	1	eq)	was	added.		
After	30	minutes,	the	reaction	was	quenched	with	5mL	NaHCO3.		The	solution	was	left	to	stir	
for	15	minutes.		The	mixture	was	extracted	with	EtOAc	(3x5mL).		The	combined	organic	layers	
were	dried	with	Na2SO4,	filtered,	and	evaporated	in	vacuo.		The	residue	was	purified	by	flash	
chromatography	on	silica	gel	(5-100%)	EtoAC:hexanes,	followed	by	(0-15%)	dichloromethane:	
methanol,	to	afford	the	desired	product,	(2S,3R)-1-acryloyl-N-(6-bromonaphthalen-2-yl)-3-
hydroxypyrrolidine-2-carboxamide	(6.6mg,	11%	yield),	as	a	white	powder.		
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HRMS	
C18H17BrN2O3Na	[M+Na]+	expected	mass:	411.032;	observed:	411.0328.	1H	NMR	(400	MHz,	
MeOD,	75:25	rotamers)	δ	8.25	(s,	1H),	7.99	(s,	1H),	7.76	(dd,	J=9.85,	9.10,	1H),	7.69	(d,	J=8.55,	
1H),	7.65	(dd,	J=8.55,	2.01,	1H),	7.53	(m,	1H),	(6.68+6.43)	(dd,	J=16.93,	10.49,	1H),	6.28	
(J=16.84,1.90,	1H),	(5.78+5.71)	(dd,	J=10.51,	1.90,	1H),	4.70	(m,	1H),	4.67	(m,	1H),	3.96	(m,	1H),	
3.74	(m,	2H),	2.21	(m,	1H).	13C	NMR	(500	MHz,	MeOD,	75:25	rotamers)	δ	170.00,	167.25,	
137.93,	133.70,	133.04,	(130.70+130.64),	(130.60+130.58),	(130.45+130.50),	129.47,	128.80,	
128.59,	(122.64+122.46),	119.40,	117.90,	(71.88+73.55),	(66.03+66.21),	(46.47+45.57),	
(34.04+31.83).	
	
11	and	12	were	synthesized	and	characterized	as	described	in	Ostrem	et	al.6	
Acrylamide	library	(N=62)	synthesis	is	described	in	Bateman	et	al	and	Roberts	et	al.50,51		
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CHAPTER	3	
	
G13C	is	a	fast	exchanging	mutant	that	is	amenable	to	covalent	binding	
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3.0	Gloss		
K-Ras(G12C)	as	an	oncogenic	target	has	experienced	breakthrough	recently	in	the	
pharmaceutical	industry	with	the	advent	of	a	line	of	covalent	inhibitors	such	as	ARS-1620	and	
AMG-510	that	reside	in	the	switch	II	pocket.	Given	its	recent	success,	one	must	look	from	
residue	12	to	residue	13	which	this	merely	one	codon	away	and	is	also	often	mutated	
frequently	in	K-Ras	driven	cancers.	K-Ras(G13C),	an	analogous	cancer-causing	mutation	in	Ras,	
is	a	rather	understudied	mutation.	Little	about	the	biochemistry	of	the	mutant	and	its	
druggability	is	commonly	known.	Here,	we	hope	to	investigate	the	bio	chemistry	of	K-Ras(G13C)	
via	structural	analysis	and	nucleotide	exchange	assays.	Furthermore,	we	hope	to	probe	its	
druggability	via	covalent	library	screening,	and	covalent	docking	technologies.	Summarily,	K-
Ras(G13C)	is	a	nucleophilic	oncogenic	cysteine	that	appears	to	be	a	fast	exchanging	activating	
mutant	that	is	amenable	to	covalent	inhibition.	
	
3.1	Introduction	
The	etiology	of	allelic	variation	in	K-Ras-driven	cancers	remains	an	unanswered	question	
to	date52-54.	For	example,	K-Ras(G12C)	is	mutated	in	40%	of	K-Ras	driven	lung	adenocarcinomas,	
while	K-Ras(G13C)	is	mutated	in	1%	of	that	patient	population	although	codon	12	and	13	are	
adjacent55,56.	Biochemical	and	cellular	studies	on	other	G12	and	G13	mutants	show	that	many	
G12	mutants	appear	to	be	more	transforming	than	their	G13	counterparts57-59.	The	G13C	
mutation	lacks	biochemical	characterization	to	explain	its	difference	to	G12C	in	oncogenicity	
and	clinical	phenotype60.	Furthermore,	G12C	inhibitors	are	unable	to	fully	modify	K-Ras(G13C),	
necessitating	an	alternative	strategy	to	drug	this	oncogenic	mutation.	Modeling	K-Ras(G13C)	
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and	K-Ras(G13D)	shows	that	residue	13	is	connected	to	the	nucleotide	binding	pocket	via	a	
hydrogen	bonding	network,	which	could	be	partially	disrupted	by	the	mutation	to	a	bulkier	
mutant	residue.	Structural	and	biochemical	data	show	that	the	K-Ras(G13C)	could	be	amenable	
to	both	nucleotide	binding	inhibition	or	allosteric	inhibition	to	the	switch	II	pocket	utilizing	high	
throughput	screening	methods	such	as	disulfide	tethering,	electrophile	inhibition,	and	covalent	
docking.	
K-Ras(G12C)	is	likely	to	be	the	first	K-Ras	mutation	to	be	targeted	molecularly	due	to	the	
specificity	of	the	covalent	inhibitors	developed	from	Wellspring	Biosciences	and	Amgen6,8-10.	
We	have	gotten	to	the	point	where	the	G12C	inhibitors	are	able	to	shrink	patient	derived	
mouse	xenografts	and	reduce	tumor	burden	in	patients	that	carry	that	mutation.	K-Ras(G13C)	is	
a	similarly	situated	oncogenic	mutation.	Modeling	K-Ras(G12C)	and	K-Ras(G13D)	shows	that	
residue	13	is	connected	to	the	nucleotide	binding	pocket	via	a	hydrogen	bonding	network,	
which	could	be	partially	disrupted	by	the	mutation	to	a	bulkier	mutant	residue.	Structural	and	
biochemical	data	show	that	the	K-Ras(G13C)	could	be	amenable	to	allosteric	inhibition	utilizing	
high	throughput	screening	methods	such	as	covalent	docking	and	mass	spectrometry	based	
electrophile	inhibition.	The	results	shown	in	this	manuscript	render	K-Ras(G13C)	amenable	to	
covalent	drug	binding.	
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Figure	3.2.1:	K-Ras(G13)	participates	in	nucleotide	recognition	through	a	hydrogen-bond	
network.	Structure	of	GDP-bound	(PDB:	4OBE)	and	GNP-bound	K-Ras	(PDB:	3GFT).		
	
3.2	K-Ras(G13C)	is	important	for	nucleotide	recognition	
	 Structural	analysis	of	GDP-	and	GppnHP-bound	K-Ras	show	that	glycine	13	participates	
in	nucleotide	recognition	in	the	p-loop	(Figure	3.2.1).	This	key	residue	13	is	connected	via	a	
hydrogen	bonding	network	from	lysine	117	to	the	beta-phosphate	of	GDP.	Lysine	117	
participates	in	core	hydrophobic	interactions	with	the	guanosine	base.	Modification	of	K117,	
such	as	ubiquitination,	or	mutations	such	as	K117N	alter	intrinsic	nucleotide	exchange	by	
drastically	decreasing	affinity	for	guanosine	diphosphate	or	trisphosphate.		It	is	likely	that	
mutations	to	glycine	13	may	also	affect	nucleotide	exchange	by	destabilizing	the	protein’s	
nucleotide	recognition.	Hunter	et	al	demonstrate	that	K-Ras(G13D)	is	a	fast	exchanger	via	
mant-based	nucleotide	exchange	assays.5	
We	examined	the	effect	of	K-Ras(G13C)	on	nucleotide	recognition	in	vitro	using	a	
fluorescent	nucleotide	exchange	assay.	EDTA-mediated	nucleotide	exchange	of	BODIPY-GDP	
and	GTP	were	performed	on	mutant	forms	of	K-Ras1-189		GDP	constructs.	Compared	to	K-
Ras(G12C)	and	wild	type-Ras,	K-Ras(G13C)	showed	increased	exchange	of	BODIPY-	labeled	GDP	
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and	GTP	analogues	(Figure	3.2.2b-c).	This	may	indicate	that	G13C	is	may	be	destabilizing	the	
nucleotide	binding	pocket.	
We	examined	the	melting	temperatures	of	the	mutant	K-Ras1-189	GDP	constructs	via	a	
thermal	stability	assay	(Figure	3.2.2d).		K-Ras(G13C)	demonstrated	a	Tm	of	53.6±0.1ºC,	which	
was	markedly	lower	than	the	wild	type	(59.3±0.1ºC)	and	G12C	(61.1±0.1ºC)	(Figure	3.2.2e).	This	
evidence	indicates	that	K-Ras(G13C)	is	a	destabilizing	mutation.	
	
	
	
Figure	3.2.2:	K-Ras(G13C)	is	a	destabilizing	mutant	a.	4-12%	bis-tris	Nupage	polyacrylamide	gel	
of	K-Ras1-189	constructs.		EDTA-mediated	nucleotide	exchange	of	b.	BODIPY-FL	GDP	and	c.	
BODIPY-FL	GTP	into	K-Ras1-189	constructs.	d.	thermal	stability	assay	on	K-Ras1-189	constructs	and	
e.	the	Tm	melting	temperatures.	
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Figure	3.3:	K-Ras(G13C)	is	amenable	to	covalent	nucleotide	labeling	a.	Structure	of	K-RasG13D	
(PDB:	4TQA)	depicting	the	nucleotide	binding	pocket	and	distance	(6.0Å)	to	3-OH	GDP.			b.	
Percent	modification	of	K-Ras(G13C)	with	covalent	GTP	analogues.	c.	structures	of	GTP	
analogues.	
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3.3	K-Ras(G13C)	is	more	amenable	to	covalent	bond	formation	via	covalent	nucleotides		
	 	
K-Ras(G13C)	is	structurally	closer	to	the	nucleotide	binding	pocket	than	G12C,	and	
therefore	the	possibility	of	nucleotide	inhibition	is	not	precluded	(Figure	3.3a).	Furthermore,	
given	the	evidence	that	K-Ras(G13C)	is	a	destabilizing	mutation	that	may	weaken	nucleotide	
affinity,	it	is	likely	possible	that	K-Ras(G13C)	can	be	drugged	by	a	covalent	nucleotide	analogue.	
A	series	of	200uM	GTP-analogues	were	used	to	treat	4uM	K-Ras(G12C)	and	G13C	over	24	hours	
in	the	presence	of	5mM	EDTA	and	percent	modification	was	monitored	via	mass	spectrometry	
(Figure	3.3b-c).	None	of	the	analogues	labeled	G12C	but	a	few	modified	G13C	partially	
indicating	that	G13C	is	more	accessible	to	covalent	capture	by	nucleotide	analogues	(Figure	
3.3b-c).	However,	cell	permeability	of	nucleotide	analogues	remains	a	difficult	task	to	achieve,	
as	seen	by	prior	attempts	to	drug	G12C	covalently.	
	
3.4	K-Ras(G13C)	is	minimally	reactive	to	available	K-Ras(G12C)	inhibitors	
The	switch	II	pocket	remains	a	tractable	pocket	for	K-Ras(G13C)	inhibition.		K-Ras(G13D)	
(PDB	ID:	4TQA)	was	aligned	to	a	structure	of	K-Ras	bound	to	a	switch	II	pocket	inhibitor	(PDB	ID:	
4M21)	with	the	inhibitor	represented	in	spheres	(slate).	From	the	alignment,	one	can	see	that	
codon	13	is	slightly	farther	away	from	the	switch	II	pocket.	This	suggests	the	necessity	for	a	
longer	switch	II	pocket	inhibitor	to	fully	occupy	the	pocket.	However,	there	is	a	possibility	that	
the	switch	II	pocket	series	may	covalently	modify	G13C.	Twenty	four	hour	treatment	of	200uM	
K-Ras(G12C)	inhibitors	to	G12C	and	G13C	(Figure	3.4b)	demonstrate	that	the	current	series	of	
switch	II	pocket	inhibitors	(compounds	1-4:	12,	ARS-853,	ARS-1620,	AMG-510)	are	minimally	
able	to	covalently	modify	G13C	in	their	current	form.	This	indicates	that	G12C	and	G13C	are	
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fundamentally	different	in	either	reactivity	or	orientation	to	the	switch	II	pocket.	Perhaps,	linker	
design	of	the	switch	II	pocket	inhibitors	may	be	necessary	in	order	to	reach	the	switch	II	pocket	
from	residue	13,	which	is	about	3.3Å	further	away.	
	
	
	
	
	
Fig	3.4:	K-Ras(G13C)	screened	with	current	switch	II	pocket	inhibitors	a.	Structural	alignment	
of	K-Ras(G12C)	(yellow,	PDB	ID:	4M21)	bound	to	a	switch	II	pocket	inhibitor	(slate)	and	K-
Ras(G13D)	(white,	PDB	ID:	4TQA).	B.	Percent	modification	of	K-Ras(G12C)	inhibitors	to	K-
Ras(G12C)	and	K-Ras(G13C)	by	mass	spectrometry.	C.	Percent	modification	of	electrophiles	
towards	K-Ras(G12C)	and	K-Ras(G13C)		d.	Chemical	structures	of	select	K-Ras	inhibitors.			
	
	
3.5	Optimizing	K-Ras(G13C)	linker	design	via	covalent	docking	
	
In	optimizing	G12C	inhibitors	for	K-Ras(G13C),	one	must	consider	the	distance	and	angle	
constraints	necessary	to	achieve	covalent	binding	at	residue	13,	given	its	further	distance	from	
the	switch	II	pocket	and	potential	rotameric	differences	to	G12C.	Covalent	docking	via	
DOCKOVALENT3.7	was	used	to	achieve	this	linker	design.		From	a	library	of	2000	boc-protected	
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diamines,	derivatives	of	compound	5	were	virtually	constructed.	After	pre-generating	all	
protomers	and	stereoisomers,	the	virtual	library	were	constrained	to	only	the	conformers	that	
achieved	a	distance	criteria	of	10.8Å	(from	the	thiol	of	G13C	to	the	base	nitrogen	in	the	
piperazine	ring)	and	maintain	critical	hydrogen	bonds	to	K16,	D69,	H95.	From	the	8	compounds	
that	were	chosen	from	covalent	docking,	only	compound	6	labeled	G13C	via	mass	spectrometry	
(Figure	3.5b).	
After	incubation	of	compounds	5	and	6	on	K-Ras	for	5	days,	the	compounds	modified	
Ras	partially	(Figure	3.5d).	Upon	a	thermal	stability	assay,	compound	6	increased	stabilization	
of	Ras	by	1C	(Figure	3.5c-d).	Structure-activity-relationships	around	compound	6	to	derive	
compounds	7	and	8	did	not	improve	labeling	K-Ras	G13C,	and	in	fact	abrogated	binding,	
indicating	that	small	molecule	recognition	is	achieved	by	more	than	linker	length.	
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Figure	3.5:	K-Ras(G13C)	screened	with	covalent	docking	analogs	a.	Structure	of	covalent	
docking	hits	and	analogues.		b.	%	Modification	of	compounds	5	and	6	to	K-Ras(G12C)	and	K-
Ras(G13C)	c.	thermal	stability	of	the	adducts	and	d.	%	modification	and	melting	temperatures.	
	
	
	
	
	
	
Fig	3.6:	Structure-activity-relationships	around	compound	9.	a.	Structure	of	electrophile	hits	
and	analogues.	%	Modification	of	compounds	9-11	to	b.	GDP-bound	and	c.	GTP-bound	K-
Ras(G12C)	and	K-Ras(G13C)	
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3.6	Electrophile	library	screening	of	G13C	reveals	new	scaffold	
	
4uM	K-Ras(G13C)	GDP	was	screened	against	a	library	of		993	commercially	available	
acrylamides	and	cloroacetamides	were	used	to	screen	at	4C,	24h,	200uM	compound,	5mM	
EDTA.	98	compounds	labeled	>50%	in	the	primary	screen.	Since	many	of	the	compounds	were	
known	promiscuous	binders	to	other	targets,	9	compounds	were	chosen	based	on	their	well	
behaved	nature	for	a	follow-up	dose	response.	Compound	9	demonstrated	a	common	motif,	a	
urea	linker,	that	is	not	frequently	seen	in	hits	and	was	retested	against	K-Ras(G12C)	and	G13C	
in	the	presence	of	1mM	MgCl2,	at	room	temperature	24	hours.	Compound	9	and	its	
commercially	available	analogues	(10	and	11)	both	label	the	GDP-bound	version	of	K-Ras(G13C)	
more	than	G12C	(Figure	3.6),	indicating	that	there	is	selectivity	towards	the	G13C	oncogene.	
Furthermore,	these	compounds	also	label	the	GTP-bound	versions	of	G12C	and	G13C.	This	
indicates	that	this	class	of	compounds	may	be	recognizing	an	alternative	pocket	to	the	GDP-
restricted	switch	II	pocket.		
	
3.7	Conclusion	
The	work	presented	in	this	thesis	highlights	the	evolution	of	K-Ras	from	an	undruggable	
target	to	one	that	can	be	effectively	targeted	with	mutant-specific	covalent	drugs.	Covalent	
inhibitors	remain	a	tangible	solution	to	targeting	the	elusive	K-Ras	oncogene,	given	the	
efficatiousness	of	K-Ras	inhibitors	currently	in	phase	I	clinical	trials.	The	switch	II	pocket	was	
discovered	to	be	an	allosteric	drug	binding	site	that	is	accessible	and	stable	with	covalent	
tethering	from	the	oncogenic	mutation,	G12C.	Since	the	switch	II	pocket	has	been	proven	to	be	
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an	effective	drug	pocket	for	K-Ras(G12C),	this	opens	the	avenue	for	other	K-Ras	mutants	to	be	
treated	via	modification	of	existing	switch	II	pocket	inhibitors.		
K-Ras(G12C)	has	been	shown	to	be	amenable	to	covalent	inhibition	via	several	switch	II	
pocket	analogs.	This	usually	works	through	an	allosteric	trapping	mechanism	which	traps	G12C	
in	a	stable	inactive,	GDP	bound	state	that	is	resistant	to	SOS-driven	nucleotide	exchange.	
However,	covalent	binders	can	also	render	the	protein	complex	unstable.	Therefore,	there	is	a	
possibility	that	upon	binding,	K-Ras	is	destabilized	allowing	it	to	undergo	faster	SOS-driven	
nucleotide	exchange.	The	work	here	shows	that	the	K-Ras	mutants	are	structurally	and	
biochemically	distinct	and	may	require	several	iterations	of	modification	before	achieving	
mutant-specific	inhibition	seen	in	G12C.		
	
3.8	Experimental	Methods	
Protein	expression	and	purification	
K-Ras	constructs	were	purified	as	previously	specified.6	Briefly,	His6-tagged	recombinant	
bacterial	human	K-Ras	(isoform	2,	residues	1-169),	K-Ras	Cys-light	(isoform	2,	residues	1-169,	
C51S/C80L/C118S),	K-Ras	(isoform	2,	residues	1-	189)	were	transformed	into	Escherichia	coli	
(BL21	(DE3))	for	expression.	K-Ras(G13C)	was	introduced	into	each	vector	using	a	QuikChangeTM	
PCR	protocol.	Protein	cultures	were	grown	in	TB	with	kanamycin	at	37˚C.	Upon	an	optical	
density	(OD600)	reached	0.5-0.6,	were	induced	at	18˚C	with	120mg	IPTG	and	expressed	over	18	
hours.	The	cells	were	pelleted	at	4,5000	rpm,	resuspended	in	lysis	buffer	(500	mM	NaCl,	20	mM	
TRIS	pH	8.0,	5	mM	imidazole,	1	tablet	of	Roche	cOmplete	EDTA	Free	protease	inhibitor	per	
50mL	lysis	buffer),	and	lysed	by	microfluidizer	at	80psi.	The	lysate	was	spun	down	at	10,000g	
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and	purified	by	batch	binding	using	TALON	beads	with	elution	buffer	(500	mM	NaCl,	20	mM	
TRIS	pH	8.0,	250	mM	imidazole).	The	His6-tag	was	cleaved	with	TEV	overnight	with	cleavage	
buffer	(300	mM	NaCl,	20	mM	TRIS	pH	8.0,	5	mM	imidazole,	1	mM	DTT,	0.5	mM	EDTA).	The	tag	
was	removed	via	Nickel	NTA	beads	and	the	eluate	was	purified	by	FPLC	using	ion	exchange	
(buffer	A:	50mM	NaCl,	20	mM	TRIS	pH	8.0,	buffer	B:	500mM	NaCl,	20	mM	TRIS	pH	8.0).	The	
protein	was	concentrated	to	5-20	mg/ml.	If	the	protein	was	used	for	crystallography	or	
hydrogen-deuterium	exchange,	it	was	subject	to	a	subsequent	size	exclusion	chromatography	
(buffer:	20	mM	HEPES	(pH	7.5),	150	mM	NaCl)	and	concentrated.	
Mass	Spectrometry	Screening	
50uL	of	4uM	K-Ras(G12C)	1-169	(buffer:	20mM	HEPES	pH	7.5,	150mM	NaCl,	1mM	
MgCl2)	was	incubated	with	200uM	compound	(4%	v/v	dimethylsulfoxide	respectively)	for	24	
hours	at	room	temperature.	The	reaction	was	quenched	with	2uL	10%	v/v	formic	acid	to	yield	
0.4%	v/v	formic	acid	final.	Mass	spectrometry	experiments	were	performed	using	the	Waters	
Acquity	UPLC/ESI-TQD	with	a	2.1 × 50 mm	Acquity	UPLC	BEH300	C4	column.	
Nucleotide	Exchange	Assay		
45uL	of	K-Ras	1-189	GDP	(111nM)	was	prepared	in	assay	buffer	(150mM	NaCl,	20mM	
HEPES,	pH	7.5,	2uM	MgCl2,	0.01%	Triton	X-100)	was	added	to	a	96	well	Costar	plate.	Exchange	
was	catalyzed	by	the	addition	of	5uL	of	a	mixture	of	0.5uM	EDTA	and	5uM	incoming	nucleotide	
(500nM	final;	ThermoFischerTM	BODIPY-FL	GDP	or	GTP)	and	fluorescence	intensity	was	
monitored	over	1	hour	at	Ex/Em:	485/520nm	using	a	BioTek	H4.	
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Thermal	Stability	Assays	
The	thermal	denaturation	of	K-Ras	was	monitored	using	a	fluorescence-based	
differential	scanning	fluorimetry	assay.	K-Ras	was	purified	with	or	without	compound	for	the	
use	of	the	experiment	as	previously	described.	8uM	protein	was	prepared	in	assay	buffer	
(150mM	NaCl,	20mM	Hepes,	pH	7.5,	1mM	MgCl2)	with	1/1000	Sypro	Orange.		The	plate	was	
heated	from	25-95°C	at	a	rate	of	0.5°C	/min.		The	fluorescence	intensity	was	monitored	at	
Ex/Em:	492/610nm.	
Synthetic	Methods	
All	commercial	reagents	were	purchased	and	used	without	further	purification	(Compounds	1-
4,	9-11).		
	
Nucleotide	analogues	A-E	were	obtained	from	Roger	Goody	and	Joseph	Piccirilli.	
A.	3`-BDA-2`-dGTP	Acryloyl		
B.	2`,3`-EDA-GTP	Acryloyl		
C.	2`,3`-PDA-GTP	Acryloyl	
D.	3C-Acryloyl-GTP	
E.	4C-Acryloyl-GTP	
EDA	-	Ethylendiamine	
PDA	-	Propylendiamine	
BDA	-	Butylendiamine	(all	attached	to	the	ribose)	
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Silica	gel	chromatography	was	performed	using	a	Combiflash	Rf	(Teledyne	Isco)	with	pre-packed	
4-24g	silica	columns	and	cartridges.		Reverse-phase	high	performance	liquid	chromatography	
(RP-HPLC)	was	performed	using	a	Waters	2545	solvent	delivery	system	equipped	with	an	
XBridge	prep	C18	column.	Separation	was	achieved	using	a	gradient	between	5-95%	
acetonitrile	(ACN)	in	water	with	0.1%	formic	acid	unless	otherwise	specified	by	monitoring	UV	
absorption	(λ=254	nm).	1H	NMR	were	recorded	on	a	Varian	Innova	400	MHz	or	a	Bruker	DRX	
500	MHz	spectrometer.	1H	chemical	shifts	are	reported	in	δ	(ppm)	as	s	(singlet),	d	(doublet),	dd	
(doublet	of	doublets),	t	(triplet),	q	(quartet),	or	m	(multiplet)	and	are	referenced	to	the	residual	
solvent	peak.		Coupling	constants	(J)	are	reported	as	Hertz.	
	
Compound	5	was	synthesized	as	described.49	
	
Compound	6	
	
7-bromo-4,6-dichloroquinazoline	(50mg,	1	eq,	0.18	mmol)	and	tert-butyl	3-oxo-4-(piperidin-3-
yl)piperazine-1-carboxylate	(57mg,	1.1	eq,	0.20	mmol)	were	dissolved	in	2	mL	ethanol.		DIPEA	
was	added	(94uL,	3	eq,	0.54	mmol)	at	ambient	temperature,	reaction	was	stirred	and	
monitored	3.5	hours	and	then	was	quenched	with	5mL	H2O	and	extracted	with	ethyl	acetate	
(5mL	x	3).	The	organic	layers	were	washed	with	brine	(2x5mL)	and	dried	over	Na2SO4.		The	
residue	was	purified	by	flash	chromatography	on	silica	gel	(0-100%	hexanes:EtOAc	gradient,	
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followed	by	0-10%	EtOAc:MeOH)	to	yield	the	desired	product	tert-butyl	4-(1-(7-bromo-6-
chloroquinazolin-4-yl)piperidin-3-yl)-3-oxopiperazine-1-carboxylate	(32mg,	34%	yield).		
tert-butyl	4-(1-(7-bromo-6-chloroquinazolin-4-yl)piperidin-3-yl)-3-oxopiperazine-1-carboxylate	
(32mg,	1	eq,	0.06mmol),	5-methyl-1H-indole-4-boronic	acid	(43mg,	4	eq,	0.24mmol),	Na2CO3	
(26mg,	4	eq,	0.24mmol),	Pd(PPh3)4	(14mg,	0.2	eq,	0.01mmol)	were	dissolved	in	1,4-dioxane	(1	
mL)	and	H2O	(0.2mL)	in	a	septum-topped	vial.	The	solution	was	sparged	with	Argon	for	10	
minutes.	The	mixture	was	stirred	overnight	at	100°C.	The	mixture	was	the	diluted	with	5mL	
H2O	and	extracted	with	ethyl	acetate	(5mL	x	3).	The	organic	layers	were	washed	with	brine	
(2x5mL)	and	dried	over	Na2SO4.		The	residue	was	purified	by	flash	chromatography	on	silica	gel	
((0-100%	hexanes:EtOAc	gradient,	followed	by	0-10%	EtOAc:MeOH	gradient)	to	yield	the	
desired	product	tert-butyl	4-(1-(6-chloro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperidin-
3-yl)-3-oxopiperazine-1-carboxylate	(20.2mg,	57.5%	yield).		
	
The	product	was	dissolved	in	1mL	dichloromethane	(DCM).		The	mixture	was	cooled	to	0°C	and	
500uL	trifluoroacetic	acid	(TFA)	was	added.	After	2	hours,	the	solvent	and	excess	TFA	was	
removed	in	vacuo	with	3x	5mL	toluene.	The	crude	product,	1-(1-(6-chloro-7-(5-methyl-1H-
indazol-4-yl)quinazolin-4-yl)piperidin-3-yl)piperazin-2-one,	was	used	without	further	
purification	as	a	yellow	oil.	
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1-(1-(6-chloro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl)piperidin-3-yl)piperazin-2-one	
(20.2mg,	1	eq,	0.042mmol),	was	dissolved	in	2mL	acetonitrile.		TEA	(11.8uL,	2eq,	0.084mmol)	
was	added	at	ambient	temperature.		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(3.4uL,	
1.1	eq,	0.0424mmol)	was	added.		The	reaction	was	quenched	with	5mL	saturated	NaHCO3	and	
left	stirring	for	15	minutes	at	ambient	temperature.			The	reaction	was	extracted	with	ethyl	
acetate	(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	HPLC	(25-95%	
acetonitrile:water)	to	get	the	desired	product	(2.8mg,	11.6%	yield).	1H	NMR	(400	MHz,	
Methanol-d4)	δ	8.63	(s,	1H),	8.51	(s,	1H),	8.31	(s,	1H),	7.77(s,	1H),	7.56	(d,	J=8.58Hz,	1H),	7.40	(d,	
J=8.84	Hz,	1H),	6.28	(dd,	J=16.81,	1.91	Hz,	1H),	5.81	(J=10.70,	1.68,	1H),	4.69	(m,	1H),	4.48	(t,	
J=14.866,	2H),	3.96	(m,	1H),	3.85	(m,	2H),	3.57	(m,	2H),	3.39	(t,	J=11.74,	2H),	3.22	(t,	J=11.86,	
2H),	2.22	(s,	3H),	2.02	(m,	4H).	NH	missing	due	to	exchange	with	Methanol-d4.	
	
Compound	7	
	
7-bromo-4,6-dichloroquinazoline	(50mg,	1	eq,	0.18	mmol)	and	tert-butyl	4-(3-
piperidyl)piperazine-1-carboxylate	(53mg,	1.1	eq,	0.20	mmol)	were	dissolved	in	2	mL	ethanol.		
DIPEA	was	added	(94uL,	3	eq,	0.54	mmol)	at	ambient	temperature,	reaction	was	stirred	and	
monitored	3	hours	and	then	was	quenched	with	5mL	H2O	and	extracted	with	ethyl	acetate	
(5mL	x	3).	The	organic	layers	were	washed	with	brine	(2x5mL)	and	dried	over	Na2SO4.		The	
residue	was	purified	by	flash	chromatography	on	silica	gel	(0-15%	DCM:MeOH)	to	yield	the	
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desired	product	tert-butyl	4-[1-(7-bromo-6-chloro-quinazolin-4-yl)-3-piperidyl]piperazine-1-
carboxylate	(45mg,	49%	yield).		
tert-butyl	4-[1-(7-bromo-6-chloro-quinazolin-4-yl)-3-piperidyl]piperazine-1-carboxylate	
	(45mg,	1	eq,	0.087mmol),	5-methyl-1H-indole-4-boronic	acid	(61mg,	4	eq,	0.35mmol),	Na2CO3	
(37mg,	4	eq,	0.35mmol),	Pd(PPh3)4	(20mg,	0.2	eq,	0.018mmol)	were	dissolved	in	1,4-dioxane	(1	
mL)	and	H2O	(0.2mL)	in	a	septum-topped	vial.	The	solution	was	sparged	with	Argon	for	10	
minutes.	The	mixture	was	stirred	overnight	at	100°C.	The	mixture	was	the	diluted	with	5mL	
H2O	and	extracted	with	ethyl	acetate	(5mL	x	3).	The	organic	layers	were	washed	with	brine	
(2x5mL)	and	dried	over	Na2SO4.		The	residue	was	purified	by	flash	chromatography	on	silica	gel	
((0-100%	hexanes:EtOAc	gradient,	followed	by	0-10%	EtOAc:MeOH	gradient)	to	yield	the	
desired	product	tert-butyl	4-[1-[6-chloro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]-3-
piperidyl]piperazine-1-carboxylate	(47	mg,	97%	yield).		
	
The	product	was	dissolved	in	1mL	dichloromethane	(DCM).		The	mixture	was	cooled	to	0°C	and	
500uL	trifluoroacetic	acid	(TFA)	was	added.	After	2	hours,	the	solvent	and	excess	TFA	was	
removed	in	vacuo	with	3x	5mL	toluene.	The	crude	product,	6-chloro-7-(5-methyl-1H-indazol-4-
yl)-4-(3-piperazin-1-yl-1-piperidyl)quinazoline,	was	used	without	further	purification.	
6-chloro-7-(5-methyl-1H-indazol-4-yl)-4-(3-piperazin-1-yl-1-piperidyl)quinazoline	(20.2mg,	1	eq,	
0.042mmol),	was	dissolved	in	1mL	acetonitrile.		TEA	(11.8uL,	2eq,	0.084mmol)	was	added	at	
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ambient	temperature.		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(3.4uL,	1.1	eq,	
0.0424mmol)	was	added.		The	reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	
stirring	for	15	minutes	at	ambient	temperature.			The	reaction	was	extracted	with	ethyl	acetate	
(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	HPLC	(25-95	acetonitrile:water)	
to	get	the	desired	product	(2.8mg,	11.6%	yield).	1H	NMR	(400	MHz,	Methanol-d4)	δ	8.60	(s,	1H),	
8.23	(s,	1H),	7.75	(d,	J	=	1.1	Hz,	1H),	7.56	(d,	J	=	8.3	Hz,	1H),	7.50	(d,	J	=	4.0	Hz,	1H),	7.41	(d,	J	=	
8.6	Hz,	1H),	6.76	(dd,	J	=	16.7,	10.7	Hz,	1H),	6.20	(dd,	J	=	16.8,	2.0	Hz,	1H),	5.75	(dd,	J	=	10.6,	2.0	
Hz,	1H),	4.62	–	4.57	(m,	2H),	3.70	–	3.62	(m,	4H),	2.79	–	2.70	(m,	4H),	2.23	(d,	J	=	3.5	Hz,	3H),	
2.19	–	2.10	(m,	1H),	2.04	–	1.97	(m,	1H),	1.80	–	1.69	(m,	2H),	0.95	–	0.84	(m,	2H).	2H	missing:	(1)	
NH	missing	due	to	exchange	with	Methanol-d4,	and	(2)	other	hidden	under	shoulder	of	solvent	
residual	peak.	
	
Compound	8	
	
7-bromo-4,6-dichloroquinazoline	(50mg,	1	eq,	0.18	mmol)	and	tert-butyl	4-(3-
piperidyl)piperidine-1-carboxylate	(53mg,	1.1	eq,	0.20	mmol)	were	dissolved	in	2	mL	ethanol.		
DIPEA	was	added	(94uL,	3	eq,	0.54	mmol)	at	ambient	temperature,	reaction	was	stirred	and	
monitored	3	hours	and	then	was	quenched	with	5mL	H2O	and	extracted	with	ethyl	acetate	
(5mL	x	3).	The	organic	layers	were	washed	with	brine	(2x5mL)	and	dried	over	Na2SO4.		The	
residue	was	purified	by	flash	chromatography	on	silica	gel	(0-15%	DCM:MeOH)	to	yield	the	
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desired	product	tert-butyl	4-[1-(7-bromo-6-chloro-quinazolin-4-yl)-3-piperidyl]piperidine-1-
carboxylate	(57mg,	62%	yield).		
tert-butyl	4-[1-(7-bromo-6-chloro-quinazolin-4-yl)-3-piperidyl]piperidine-1-carboxylate	
	(57mg,	1	eq,	0.11mmol),	5-methyl-1H-indole-4-boronic	acid	(79mg,	4	eq,	0.45mmol),	Na2CO3	
(47mg,	4	eq,	0.45mmol),	Pd(PPh3)4	(26mg,	0.2	eq,	0.022mmol)	were	dissolved	in	1,4-dioxane	(2	
mL)	and	H2O	(0.5mL)	in	a	septum-topped	vial.	The	solution	was	sparged	with	Argon	for	10	
minutes.	The	mixture	was	stirred	overnight	at	100°C.	The	mixture	was	the	diluted	with	5mL	
H2O	and	extracted	with	ethyl	acetate	(5mL	x	3).	The	organic	layers	were	washed	with	brine	
(2x5mL)	and	dried	over	Na2SO4.		The	residue	was	purified	by	flash	chromatography	on	silica	gel	
((0-100%	hexanes:EtOAc	gradient,	followed	by	0-10%	EtOAc:MeOH	gradient)	to	yield	the	
desired	product	tert-butyl	4-[1-[6-chloro-7-(5-methyl-1H-indazol-4-yl)quinazolin-4-yl]-3-
piperidyl]piperidine-1-carboxylate	(59mg,	93%	yield).		
	
The	product	was	dissolved	in	1mL	dichloromethane	(DCM).		The	mixture	was	cooled	to	0°C	and	
500uL	trifluoroacetic	acid	(TFA)	was	added.	After	2	hours,	the	solvent	and	excess	TFA	was	
removed	in	vacuo	with	3x	5mL	toluene.	The	crude	product	6-chloro-7-(5-methyl-1H-indazol-4-
yl)-4-[3-(4-piperidyl)-1-piperidyl]quinazoline,	was	used	without	further	purification.	
6-chloro-7-(5-methyl-1H-indazol-4-yl)-4-[3-(4-piperidyl)-1-piperidyl]quinazoline	(20mg,	1	eq,	
0.044mmol),	was	dissolved	in	1mL	acetonitrile.		TEA	(12uL,	2eq,	0.087mmol)	was	added	at	
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ambient	temperature.		The	reaction	was	cooled	to	0°C.		Acryloyl	chloride	(3.9uL,	1.1	eq,	
0.084mmol)	was	added.		The	reaction	was	quenched	with	5mL	saturated	NaHCO3	and	left	
stirring	for	15	minutes	at	ambient	temperature.			The	reaction	was	extracted	with	ethyl	acetate	
(5mL	x	3),	dried	over	Na2SO4.		The	compound	was	purified	by	HPLC	(25-95%	acetonitrile:water)	
to	get	the	desired	product	(1.2mg,	5.3%	yield).	1H	NMR	(400	MHz,	Methanol-d4)	δ	8.56	(d,	J	=	
13.1	Hz,	2H),	8.18	(s,	1H),	7.74	(d,	J	=	1.4	Hz,	1H),	7.56	(d,	J	=	8.6	Hz,	1H),	7.50	(d,	J	=	6.8	Hz,	1H),	
7.40	(d,	J	=	8.6	Hz,	1H),	6.84	–	6.70	(m,	1H),	6.17	(d,	J	=	16.8	Hz,	1H),	5.72	(d,	J	=	10.1	Hz,	1H),	
4.69	–	4.52	(m,	2H),	4.48	(d,	J	=	13.0	Hz,	1H),	4.18	(d,	J	=	13.1	Hz,	1H),	3.18	–	3.02	(m,	2H),	2.80	–	
2.65	(m,	1H),	2.23	(d,	J	=	4.3	Hz,	3H),	2.08	(d,	J	=	13.8	Hz,	1H),	1.95	(d,	J	=	10.3	Hz,	3H),	1.84	–	
1.68	(m,	2H),	1.67	–	1.56	(m,	1H),	1.53	–	1.40	(m,	1H),	1.39	–	1.25	(m,	2H).	NH	missing	due	to	
exchange	with	Methanol-d4.	
	
Fragment	electrophile	library	
993	covalent	fragments	-	75%	chloroacetamides,	25%	acrylamides,	all	commercially	
available,	were	assembled	from	Enamine.	Average	molecular	weight	(of	the	covalent	adduct)	is	
217	Da.		
A	full	screen	of	the	library	was	performed	using	K-Ras	G13C	(GDP)	at	4uM	protein,	
200uM	compound,	incubated	at	4C	for	24h.	The	primary	screens	were	performed	with	5	
compounds	in	each	well,	and	%	labeling	is	assigned	based	on	mass	based	on	the	methods	in	
Resnik	et	al.26	
98	compounds	labeled	>50%	in	the	primary	screen,	but	many	of	the	compounds	were	
known	promiscuous	binders.	Nine	compounds	that	looked	promising	based	of	our	knowledge	
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of	the	library	for	follow-up	dose	response.	Three	of	these	turned	out	to	be	false	positives.	Of	
the	remaining	6,	three:	PCM-0102308,	PCM-0102332,	PCM-0102705	share	a	common	motif.	
	
Table	3.8	Results	of	electrophile	library	screen	on	K-Ras(G13C)	GDP	
	
200uM 100uM 50uM 10uM
PCM-0102492 50 30 10 0
PCM-0102366 10 5 0 0
PCM-0102308 100 95 70 30
PCM-0102332 65 60 30 5
PCM-0102813 15 5 0 0
PCM-0102705 10 0 0 0
Ind1 100 90 60 10
Ind2 70 80 80 60
Ind3 100 100 90 20
PCM-0102690 0 0 0 0
PCM-0102923 0 0 0 0
PCM-0102804 0 0 0 0
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For	one	of	the	other	hits	(PCM-0102705)	analogues	(Ind1-3)	showed	significant	labeling.	
However,	indoline	chloroacetamides	are	very	reactive.		
Virtual	library	generation		
The	cysteine	rotamer	of	G13C	was	modeled	via	PyMOL	into	a	crystal	structure	of	K-
Ras(G12C)	covalently	bound	to	compound	5.	The	original	structure	was	not	deposited	in	the	
PDB.	The	primary	docking	screen	of	K-Ras(G13C)	was	carried	out	synthesizing	a	covalent	
docking	library	from	~2000	boc-protected	amines.	To	generate	the	library	for	the	secondary	
docking	screen,	we	searched	Enamine's	building	block	catalogue	for	boc-protected	amines	for	
virtual	parallel	synthesis	according	to	the	scheme	shown	here.		
We	selected	~2,000	boc-protected	diamine	building	blocks	based	on	the	following	
criteria:	MW	of	the	final	product	≤	350.	All	pre-generated	ligand	conformations	were	built	in	the	
reacted	form	represented	by	a	dummy	silicon	atom.25	Protonated	and	tautomerized	
conformations	were	generated	by	Corina	(https://www.mn-am.com/products/corina).		
Computational	workflow	of	covalent	docking	screen		
We	used	DOCKovalent	as	implemented	in	DOCK	3.7.25	For	pose	reproduction	analysis,	
the	sampling	parameters	of	covalent	bond	length	and	angle	were	set	according	to	the	value	
from	crystal	structures.	The	bump_rigid	and	bump_maximum	were	set	to	the	maximum	
values	and	check_clashes	was	changed	from	'yes'	to	'no'	to	improve	pose	sampling	by	
allowing	several	steric	clashes	between	protein	and	ligand.	The	number_save	and	
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number_write	were	modified	from	1	to	1000	to	keep	multiple	poses	for	further	analysis.	
Blastermaster.py	was	used	to	prepare	docking	systems,	and	the	parameter	margin	was	
changed	from	the	default	value	of	10Å	to	6Å	for	grid	generation.	The	cysteine	rotamer	is	
immobile	during	the	covalent	docking.	Each	conformation	of	the	sampled	compound	was	
scored	and	ranked	according	to	the	physics-based	scoring	function	in	DOCK3.7	without	
considering	the	different	conformational	energies	among	the	cysteine	rotamers.	
For	the	prospective	study,	the	covalent	bond	parameters	were	set	to	a	length=1.8Å,	
bond	angles=109.5°±10°	(in	2.5°	steps).	
Post-docking	pose	analysis		
The	RMSD	values	for	the	ligand	heavy	atoms	between	the	top-scoring	pose	and	the	
crystal	structure	was	calculated	using	an	in-house	script.	The	lowest	RMSD	of	top	1,000-scoring	
poses	was	saved	for	minimization	refinement,	and	their	RMSD	values	were	also	calculated.				
For	the	primary	docking	screen	of	G13C,	the	compounds	were	selected	based	on	ability	
to	occupy	the	hydrophobic	binding	pocket	and	meet	distance	criteria	of	10.8	Å	from	the	base	of	
the	nitrogen	in	the	boc-protected	amine	to	the	cysteine	of	G13C.			
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Figure	3.8	Distance	constraint	parameters	demonstrated	on	crystal	structure	of	K-Ras(G12C)	
with	compound	5.	Cysteine	13	and	glycine	12	are	modeled	computationally	with	Chimera.	
Distance	from	cysteine	to	piperazine	nitrogen	is	10.8Å.	
	
The	top	400	scoring	poses	for	each	compound	were	filtered	based	on	ability	to	form	
hydrogen	bonds	with	the	side	chains	of	D69,	H95	using	an	automated	script.	Finally,	the	top-
scoring	pose	for	each	compound	was	selected	for	minimization	and	ability	to	hydrogen	bond	to	
K16.		
Molecular	mechanics-based	minimization	and	MM-GB/SA	calculation	
We	further	optimized	the	geometry	of	the	protein-ligand	adducts	by	energy	
minimization6	using	AMBER	14.7	The	Antechamber	module	was	used	to	calculate	partial	charges	
using	the	semi-empirical	AM1-BCC	method	to	assign	force	field	parameters	and	to	calculate	
topology	files	for	the	ligand.	These	files	were	modified	to	create	a	covalent	adduct	by	combining	
the	ligand	topology	and	attached	lysine	residue.	Parameters	for	the	covalent	linkage	between	
ligands	and	Lys	residue	were	assigned	by	mixing	generalized	amber	force	field	(GAFF)8	
parameters	for	the	ligand	and	the	Amber	force	field	for	the	protein.	These	parameters,	located	
at	the	borderline	between	the	two	force	fields,	were	assigned	on	the	basis	of	the	analogous	
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parameters	available	for	similar	atom	types.	TLeap	was	then	used	to	prepare	the	complex	
generated	from	docking	for	molecular	mechanics.	We	used	the	sander	program	to	minimize	the	
covalent	system.	5,000	steps	of	minimization	were	carried	out	using	the	Hawkins,	Cramer,	
Truhlar	pairwise	generalized	Born	model	with	harmonic	position	restraints	on	all	heavy	atoms	
except	for	the	ligand	and	the	attached	lysine	residue.	Snapshots	of	the	receptor,	ligand,	and	
receptor-ligand	complex	(final	snapshot	after	minimization)	were	analyzed	and	the	binding	free	
energy	was	calculated	by	using	the	molecular	mechanics/generalized	Born	surface	area	
(MM/GBSA)	method:	ΔΔGbind	=	ΔGmmgbsa,complex	-	(ΔGmmgbsa,lig	+	ΔGmmgbsa,rec).	
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CHAPTER	4	
	
Summary	
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4.	Summary	
The	field	of	K-Ras	is	rapidly	expanding	to	accept	that	1.	K-Ras	mutants	behave	differently	
biochemically	and	may	be	oncogenic	in	different	ways	and	2.	That	K-Ras	might	be	a	druggable	
oncogene,	with	the	first	advances	of	switch	II	pocket	inhibitors	making	their	way	into	clinical	
trials.		Here,	we	describe	the	ways	in	which	K-Ras(G12C)	may	be	used	as	a	case	study	to	
demonstrate	that	covalent	docking	is	a	viable	strategy	for	generating	new	chemotypes	that	
bind	K-Ras.	Furthermore	we	apply	the	knowledge	utilized	from	KRas	G12C	to	study	G13C.	
Which	is	seen	as	a	different	oncogene,	whose	oncogenicity	may	occur	from	its	fast	exchanging	
phenotype.	Given	that	G13C	in	the	cell	will	be	subject	to	large	excesses	of	GTP,	it	is	feasible	that	
oncogenicity	may	be	purely	induced	by	the	disruption	of	the	nucleotide	binding	pocket	by	this	
bulkier	residue.	
In	addition,	K-Ras	G13C	cannot	be	treated	by	our	current	inventory	of	covalent	switch	II	
pocket	inhibitors	as	they	do	not	label	G12C	even	at	radically	high	doses.	This	necessitates	a	
different	strategy	to	targeting	G13C,	which	may	include	structure	activity	relationships	around	
linker	modification	of	G12C	inhibitors	or	screening	covalent	libraries	to	find	a	new	chemotype	
that	is	G13C	specific.	The	work	highlighted	in	the	manuscript	indicates	that	both	approaches	
can	yield	a	G13C	binder	yet	more	work	needs	to	be	done	to	characterize	the	binders	that	have	
originated	including	structure	activity	relationships	and	further	biochemical	characterization	
and	structural	characterization.			
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